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ABSTRACT 
Plasma proteinase inhibitors form nearly 10% of the 
total proteinase of human plasma and are implicated in a 
number of physiological processes such as connective 
tissue turnover, coagulation, fibrinolysis, complement 
activation and inflammatory reactions. Thiol proteinase 
inhibitors (TPI) in human plasma are known to inhibit 
specifically thiol proteinases. 
Available data on thiol proteinase inhibitor show 
that human plasma comprises of high and low MVJ TPI which 
differ in physiochemical properties. In view of the lack 
of information regarding several physiochemical properties 
it was thought worthwhile to investigate TPI from human 
plasma. Previously workers had isolated thiol proteinase 
inhibitors from human plasma by using different methods 
and most extensively affinity chromatography was used to 
remove unwanted proteins. In this study we have used 
simple three step procedure for isolation of TPI from 
human plasma by a modification of the method described by 
Sasaki et al. in 1981. Three steps include ammonium 
sulphate fractionation (35-55%), gel chromatography on 
Sephadex G-200 and ion exchange chromatography on DEAE 
cellulose. Four thiol proteinase inhibitory preparations 
were obtained namely TPI-1, TPI-2, TPI-3 and TPI-4. Out 
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of these, three were found to be homogeneous with respect 
to charge since in 5% PAGE they gave single band, however, 
TPI-2 was heterogeneous as it gave three bands under 
identical conditions of PAGE, no further attempt was done 
to purify it. All the four inhibitors were homogeneous 
with respect to size on Sephadex G-200 giving single 
symmetrical protein peaks. Molecular weight of the 
inhibitors as determined by gel chromatography on 
Sephadex G-200 column were 70,000; 1,55,000; 1,95,000 and 
4,97,000 for inhibitors-1, 2, 3 and 4 respectively. 
Previously workers had reported the presence of high 
(MW 1,08,000 - 1,20,000) and low molecular weight 
(MVJ 50,000 - 78,000) TPI in human plasma. In this study 
we have obtained low molecular weight TPI (TPI-1) of 
MW 70,000 which was closer to that reported by Ryley in 
1979 and a high molecular weight TPI (TPI-2) of MW 155,000 
close to one reported by Nakayasu et al in 1979 . In 
addition to these we obtained two more TPI's of molecular 
weight 1,95,000 (TPI-3) and 4,97,000 (TPI-4) respectively. 
Thus four multimolecular forms of TPI from human plasma 
were purified. 
The inhibitors had stokes radius of 3.55, 4.45, 4.8 
and 6.5 nm and a frictional ratio of 1.2, 1.25, 1.26 and 
0.92 for TPI-1, TPI-2, TPI-3 and TPI-4 respectively. 
These hydrodynamic results suggested that human plasma TPI 
like serum albumin for which frictional ratio, ^/^niin 
1.35 is likely to exist in a globular conformation under 
native conditions. SDS-PAGE in 7.5% gel gave a molecular 
weight of the subunits as 69,000 for TPI-1, 56,000 for 
TPI-3 and 52,000 for TPI-4 respectively, which indicated 
single polypeptide chain for TPI-1 whereas four and ten 
subunits for TPI-3 and TPI-4 respectively. Thiol 
proteinase inhibitor-1, TPI-3 and TPI-4 were further 
characterized for several other properties given below. 
Thiol proteinase inhibitory activity at different 
pH (3.0 - 9.0) when examined showed that the three 
proteinase inhibitors (TPI-1, TPI-3 and TPI-4) were stable 
to exposure to "pH 5.0 - 9.0. This indicated pH dependent 
activation of the three inhibitors between pH 4.0 - 5.0. 
However, below pH 5.0 all the three inhibitors were very 
labile. Thermal activity experiment showed decline in 
inhibitory activity above 40°C for TPI-1 and TPI-3, while 
TPI-4 looses its inhibitory activity above 70°C. K^ value 
when determined by double reciprocal plot yielded a value 
of 2.7 X 10"^ M, 3.2 X 10~^ M and 3.6 x lO"^ M for 
papain in the presence of TPI-1, TPI-3 and TPI-4 respec-
tively. Thiol proteinase inhibitor-1, TPI-3 and TPI-4 
inhibited papain competitively. V of TPI-1, TPI-3 and max 
TPI-4 turned out to be 15.87x10"^, 15.15 x lO"® and 
14.28 X 10"® ;amole/ml/60 min. K^^^/K^ value for papain in 
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•Che presence of TPI-1, TPI-3 and TPI-4 were 8.4 x 
M~^/sec, 7.5 X M"^/sec and 7.2 x M~^/sec 
respectively, ^i(app) determined by the method 
of Henderson which gave 14.8 x M for TPI-1, 1.33 x 
10"^° M for TPI-3 and 1.17 x M for TPI-4. 
Specificity of these proteins as thiol proteinase 
inhibitors was tested by measuring the inhibitory activity 
against papain, cathepsin B and trypsin. Papain was 
strongly inhibited than cathepsin B while trypsin remained 
uninhibited by all the three inhibitors. Thiol proteinase 
inhibitory activity at different concentrations of papain 
when determined gave papain/TPI stoichiometry of 1:1 for 
TPI-1, 1.5:1 for TPI-3 and 3.2:1 for TPI-4. Structural 
relationship between the three inhibitors and also 
including TPI-2 was examined by immunodiffusion test with 
antibody against TPI-1, gave precipitin lines which fused 
without spur formation suggested similar antigenic 
structure. This result was further supported by 
inhibition ELISA. Optical properties of TPI-1, TPI-3 and 
TPI-4 were monitored by UV spectrophotometer and spectro-
fluorometer. From the spectra it was quite clear that the 
binding between papain and the inhibitors quenched the 
absorbance of papain and the binding between them probably 
include chromophoric groups. 
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X H T R O D U G X I O N 
Proteolytic enzymes are of universal occurrence in 
living systems and perform a variety of functions. 
Depending upon the specificity of these enzymes, they have 
been classified into four classes namely serine, aspartic, 
metallo and thiol proteinases. Out of these, thiol 
proteinase play very important role in the degradation of 
intracellular proteins, collagen and other connective 
tissue proteins in vivo (1-4). Cathepsins are thiol 
enzymes present in lysosomes which are involved in 
intracellular digestion of proteins. The best 
characterized of these thiol enzymes are cathepsin B(5), 
H(6) and L(7). They are evolutionary related to papain and 
are responsible for much of the bulk turnover of proteins. 
Other cellular thiol endopeptidases present in lysosomes 
include the cytosolic Ca"*"^  dependent proteinases the 
calpains (8). Lysosomes also contain thiol exopeptidases 
such as dipeptidyl peptidase I that completes degradation 
of proteins by their rapid action on oligopeptides (9). 
The materials which accumulate inside the lysosomes by 
different modes are degraded by these lysosomal 
proteinases (cathepsin) at acid pH. Proteolysis within 
the lysosomal system is initiated by these endopeptidases 
cleaving bonds within the peptide chains and is completed 
by exopeptidase. They may effect the degradation of 
proteins destined for secretion by fusion of secretory 
vesicles with lysosomes (10) or by their
directly within the secretory vesicles (11). These 
enzymes can inactivate some native enzymes such as 
aldolase, glucokinase, pyruvate kinase (12), fructose 1,6 
diphosphatase (13), glucose-6-phosphate dehydrogenase and 
some other enzymes (14). They also play significant role 
in hormone metabolism (15) and in the cleavage of certain 
precursor proteins generating their active forms e.g. 
proinsulin to insulin (16), albumin from prealbumin (17) 
and parathyrin from proparathyrin (18). Cathepsin B plays 
significant role in these limited proteolysis. 
Cathepsins also play very important role in 
inflammatory processes and in pathogenesis of diseases 
such as rheumatoid arthritis and pulmonary emphysema which 
occurs due to proteolysis of lung structural proteins by 
cathepsin G, a proteinase released from polymorphonuclear 
leukocytes (19-21). In arthritis and joint inflammation 
there is a breakdown of extracellular proteoglycans. The 
core protein of proteoglycans is susceptible to the action 
of cathepsin B which produces peptide fragments containing 
one to several polysaccharide chains. Inflammatory 
reactions of whatever origin are accompanied by an 
increase of lysosomal membrane permeability which provokes 
at the tissue level releasing lysosomal enzyme cathepsins. 
The enzyme may come from injured connective tissue or from 
deteroid polymorphonuclear cells. In some pathological 
conditions ischaemia, hypervitaminosis and exposure to U.V 
radiations, lysosomal enzymes are released in extra-
cellular space and produce extensive damage to the 
extracellular matrix. Cathepsin B secreted from human 
pancreatic cancer cells is a variant type and may play 
important role in pancreatic cancer through destruction of 
the surrounding extracellular matrix by its proteolytic 
activity. Cathepsins have also been shown to produce 
immunoglobulin G fragments acting on human immunoglobulin 
G. The fragments act as auto antigens which leads to 
development of inflammation and polymorphonuclear 
chemotaxis. 
Exact mechanism of regulation of proteolytic activity 
is obscure todate however, available evidences suggest 
that this may occur at the level of biosynthesis or 
mediated through protein inhibitors. 
Occurrence of proteinase inhibitors has been reported 
from human, animals, plants and microorganisms (22-25). 
The precise biological function of most of these 
inhibitors is yet to be elucidated, they are believed to 
be involved in the prevention of unwanted proteolysis. 
Proteinase inhibitors have been isolated from various 
tissue of higher animals and man (26, 27) blood plasma 
(28, 29) and plasma derived interstitial fluid (30, 31). 
Now at least nine separate well characterized 
proteinase inhibitors in human plasma have been recognized 
that share the capacity to inhibit the activity of various 
proteinases (Table 1). These inhibitors constitute the 
third largest group of functional proteins in human plasma 
after albumin and immunoglobulins. 
In contrast to serine proteinase inhibitors, very 
little is known about thiol proteinase inhibitors (TPI). 
Thiol proteinase inhibitors in human plasma were first 
described in 1976 as a plasma protein with a marked 
specificity for the inactivation of thiol proteinases 
(32-40). Then in 1977 Sasaki et al (29) purified TPI from 
human serum in a functionally pure state (Mr 90,000) 
having a2~electrophoretic mobility, a tentative term, 
a2-TPI was given because of its mobility and inhibition 
spectrum. Ryley (41) purified the inhibitor, finding it 
to be a sialoglycoprotein and to be electrophoretically 
heterogeneous migrating in both a^ and positions. The 
two immunologically identical forms had different 
molecular weight values 90,000 and 170,000. They also 
reported the data for amino acid composition and 
carbohydrate content (10%). Sasaki et al in 1981 (42) 
isolated three forms of the inhibitor from human plasma 
differing in molecular weight and isoelectric point naming 
them as P-1 (Mr 90,000; pl 4.5), P-2 (Mr 95,000; pl 4.4) 
and P-3 (Mr 167,000; pl 4.1). They introduced the term 
ttj^-thiol proteinase inhibitor (a^^-TPI) for P-3 which had 
the highest Mr value and anodal mobility retaining a2-TPI^ 
for P-2 and a2-TPl2 for P-1 respectively. Gounaris et al 
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in 1984 (43) purified a-thiol proteinase inhibitor (a-TPI) 
and obtained a high molecular weight (100,000) and low 
molecular form of a-TPI (64,000). Both forms were 
sialoglycoprotein and a tight binding inhibitor of papain, 
cathepsin H and L. Pagano et al in 1984 (44) isolated two 
forms of thiol proteinase inhibitors from human serum 
namely proteinase inhibitor (Mr 90,000) and low 
molecular weight thiol proteinase inhibitor (Mr 30,000) 
and studied its kinetic parameters. From all the above 
mentioned data it can be concluded that human plasma 
contains at least two distinct forms of thiol proteinase 
inhibitor(TPI) that differ in molecular weight i.e. high 
molecular weight thiol proteinase inhibitor (a^-TPI) and 
low molecular weight thiol proteinase inhibitor (CX2-TPI). 
Properties of Thiol Proteinase Inhibitor 
Purification 
Purification of human low molecular weight thiol 
proteinase inhibitor has been reported by a variety of 
laboratories (29, 41, 45-50). In general, purification of 
thiol proteinase inhibitor requires many steps and the 
recovery from plasma is very low. The procedures reported 
by many investigators (51-54) include ion exchange column 
chromatography, gel filtration, immunoaffinity 
chromatography and starch block electrophoresis. 
Physical and Chemical Properties 
Plasma concentration of a-thiol proteinase inhibitors 
have been reported 359-425 jug/ml (41, 43). Molecular 
weight has been extensively investigated by several 
workers as mentioned earlier (28, 29, 41, 42). All the 
enzymes known to be inhibited by the thiol proteinase 
inhibitor (TPI) are proteinases with thiol active sites. 
Specificity 
Thiol proteinase inhibitors have shown no inhibition 
with trypsin, chymotrypsin, elastase, thrombin, kallikrein, 
coagulation factor Xllla (a non-proteolytic thiol 
dependent enzyme), lysosomal carboxypeptidase A and 
cathepsin D (28, 33, 43). The available data indicate 
that all TPI's inhibit the great majority of thiol 
proteinases of the papain superfamily including papain, 
chymopapain, papaya proteinase III, ficin, actinidin and 
the lysosomal thiol proteinases, cathepsins B, H and L 
(28, 33, 43, 55, 56). 
Oddly, the papain homologue from pineapple, bromelain/ 
is not inhibited by thiol proteinase inhibitors (57). The 
inhibition of calpain (calcium dependent thiol proteinase) 
by TPI was described by Sasaki et al (58). 
Carbohydrate content 
Thiol proteinase inhibitor is a glycoprotein 
containing about 10% carbohydrate and is also characterized 
by its high acidic amino acid content (41) (Table 2). 
Human contains four potential sites for 
attachment of carbohydrate chains to asparagine. These 
four sequences are located at residues 48, 169, 205 and 
294. The human molecule lacks the potential carbohydrate 
binding sites that are present in bovine LMW kininogen at 
amino acid residues 88, 170 and 198. The locations of 
other carbohydrate chain, if any, that are attached to 
threonine or serine residues are not clear at the present 
time. 
Primary structure 
The amino acid sequence of a2-TPI contained two 
repeat sequences that occur in tandem. Both sequences 
(amino acid residues 104-225 and 226-347) consist of 122 
amino acid residues with 42 identical amino acids. This 
corresponds to a homology of 34%. All six thiol residues 
in the two repeat sequences are conserved. This 
observation suggests that gene duplication has occurred in 
this protein during evolution (59-61) (Fig. A). 
A clear conservation of the sequence 
Gln-Val-Val-Ala-Gly strongly suggests that this site may 
be the reactive site for these thiol proteinase inhibitors. 
This further suggests that a^-TPI may have two reactive 
sites per molecule starting with Gln-188 and Gln-310 (59). 
Table - 2 
AMINO ACID AND CARBOHYDRATE COMPOSITION OF PLASMA THIOL 
PROTEINASE INHIBITOR 
Amino acids ;ag/mg protein (2) ;aM/mM protein 
Aspartic acid 104.8 47.2 
Threonine 68.4 34.4 
Serine 53.6 30.6 
Glutamic acid 120.5 49.1 
Proline 45.3 23.6 
Glycine 24.8 19.8 
Alanine 26.5 17.8 
Cystine^^^ 7.6 1.9 
Valine 34.9 17.9 
Methionine 4.8 1.9 
Isoleucine 47.8 21.9 
Leucine 55.8 25.5 
Tyrosine 59.8 19.8 
Phenylalanine 45.6 16.6 
Lysine 66.9 27.4 
Histidine 9.9 3.8 
Tryptophan 17.3 5.1 
Arginine 37.0 12.7 
Glucosamine 13.6 4.1 
Galactosamine 2.2 0.7 
Galactose 51.7 15.5 
Mannose 31.3 9.4 
Fucose <1.0 -
Sialic acid 30.7 6.0 
(1) Estimated after 20 h hydrolysis with 6 M HCl. 
(2) Assuming a molecular weight of 60,000. 
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Het Lys Ltu U c Thr lit Leu Phe L<u Cy> S«r Arg Leu Leu Leu Ser Leu Thr Cln Clu Ser Cln Str Clu Clu l U A>p Cyi A m Aip Ly( Anp Leu 
ATC AAA CIA ATT ACC ATC C[t TTC CTC TCC TCC ACC CTA CTA CTA ACT TTA ACC CAC CAA TCA CAC TCC CAC CAA ATT CAC TCC AAT CAC AAC CAT TTA 
SO 60 70 BO 90 100 110 120 130 U O 
40 ^ 50 60 
Pht Lyt All V>1 Aip a U Alt Leu Lyi Lyt Tyr A m Ser Cln A<n Cln Str A m A(n Cln Phe Vtl Ltu Tyr Arn lit Thr Clu Alt Thr Lyi Thr Vtl 
m AAA CCT CTC CAT CCT CCT CTC AAC AAA TAT AAC ACT CAA AAC CAA ACT AAC AAC CAC TTT CTA TTC TAC CCC ATA ACT CAA CCC ACT AAC ACC CTT liO 160 170 180 190 200 210 220 230 2iO 
70 80 90 
Cly Str Asp Thr Pht Tyr Ser Phe Lyt Tyr Clu lie Lyt Clu Cly Aip Cyt Pro Vtl Cln Ser Cly Lyt Thr Trp Cln Atp Cyt Clu Tyr Lyt Atp Alt 
' CCC TCT CAC ACC m TAT TCC TTC AAC TAC CAA ATC AAC CAC CCC CAT TCT CCT CTT CAA ACT CCC AAA ACC TCC CAC CAC TCT CAC TAC AAC CAT CCT 
ISO 260 2 70 280 290 300 310 320 330 340 
100 U O 120 130 
Alt Lyt Alt Alt Thr Cly Clu Cyt Thr Alt Thr Vtl Cly Lyt Arg Ser Str Thr Lyt Phe Ser Vtl Alt Thr Cln Thr Cyt Cln lit Thr Pro Alt Clu 
OC* AJUl CCA CCC ACT CfJV CAA TCC ACC CCA ACC CTC CCC AAC ACC ACC ACT ACC AAA TTC TCC CTC OCT ACC CAC ACC TCC CAC ATT ACT CCA CCC GAO 
350 360 370 380 390 400 410 420 430 440 
140 150 160 
Cly Pro Vtl Vtl Thr Alt Cln Tyr Atp Cyt Leu Cly Cyt Vtl Hit Pro U c Ser Thr Cln Ser Pro Atp Leu Clu Pro lit Ltu Arg Hit Cly lit Cln 
OCC CCT CTC CTC ACA CCC CAC TAC CAC TCC CTC C C C TCT CTC CAT CCT ATA TCA ACC CAC ACC CCA CAC CTC CAC CCC ATT CTC ACA CAC CCC ATT CAC 
450 460 4 70 480 490 500 510 520 530 540 
^ 170 180 190 
Tyr Phe Atn A»n A m Thr Cln Hit Ser Ser Leu Phe Met Leu Atn Clu Vtl Lyt Arg Alt Cln Arg|Cln Vtl Vtl Alt Cly| Ltu A m Phe Arg lie Thr 
TAC rrr AAC AAC AAC act CAA cat TCC TCC CTC TTC ATC CTT AAT CAA CTA AAA CCC CCC CAA ACA CAC CTC CTC CCT crjk TTC AAC TTT CCA ATT ACC 
550 560 570 580 590 600 610 620 630 
200 ^ 210 220 230 
Tyr Ser lie Vtl Cln Thr Asn Cyt Ser Lyt Clu Asn Phe Leu Phe Leu Thr Pro Asp Cyt Lyt Ser Leu Trp A m Cly Atp Thr Cly Clu Cyt Thr A«p 
TAC TCA ATT CTC CAA ACC AAT TCT TCC AAA CAC AAT TTT CTC TTC TTA ACT CCA CAC TCC AAC TCC CTT TCC AAT CCT CAT ACC CCT CAA TCT ACA CAT 
640 650 660 670 680 690 ' 700 710 720 730 
240 250 260 
Ata Alt Tyr lit Atp lie Cln Leu Arg lie A U Ser Pht Ser Cln Atn Cyt Atp lit Tyr Pro Cly Lyt Atp Phe Vtl Cln Pro Pro Thr Lyt lit Cyt 
AAT CCA TAC ATC CAT ATT CAC CTA CCA ATT CCT ICC TTC TCA CAC AAC TCT' CAC ATT TAT CCA CCC AAC CAT TTT CTA CAA CCA CCT ACC AAC ATT TCC 
740 750 760 770 780 790 800 810 820 830 
270 280 290 ^ 
Val Cly Cyt Pro Arg Atp lie Pro Thr Asn Ser Pro Clu Leu Clu Clu Thr Leu Thr Hit Thr lie Thr Lyt Leu Atn Alt Clu A m Atn Alt Thr Pht 
CTC CCC TCC CCC ACA CAT ATA CCC ACC AAC ACC CCA CAC CTC CAC CAC ACA CTC ACT CAC ACC ATC ACA AAC CTT AAT CCA CAC AAT AAC CCA ACT TTC 
fr40 850 860 8 70 8!>0 890 )00 910 920 930 
300 310 320 330 
Tyr Pht Lyt lie Atp A m Vtl Lyt Lyt Alt Arg Vtl|Cln Vtl Val Alt Cly| Lyt Lyt Tyr Phe lit Atp Pht Val Alt Arg Clu Thr Thr Cyt Ser Lyt 
TAT TTC AAC ATT CAC AAT CTC AAA AAA CCA ACA CTA CAC CTC CTC CCT CCC AAC AAA TAT TTT ATT CAC TTC CTC CCC ACC CAA ACC ACA TCT TCC AAC 
940 950 960 970 980 990 1000 1010 1020 1030 
340 350 360 
Clu Str Atn Clu Clu Ltu Thr Clu Ser Cyt Clu Thr Lyt Lyt Ltu Cly Cln Str Ltu Atp Cyt Atn Alt Clu Vtl Tyr Vtl Vtl Pro Trp Clu Lyt Lyt 
CAA ACT AAT CAA CAC TTC ACC CAA ACC TCT CAC ACC AAA AAA CTT CCC CAA ACC CTA CAT TCC AAC CCT CAA CTT TAT CTC CTA CCC TCC CAC AAA AAA 
1040 1050 lOfcO 1070 1080 1090 1100 1110 IIJO 1130 
370 380 ^  ^ 3 9 0 
lit Tyr Pro Thr Vtl A m Cyt Cln Pro Leu Cly Met lie Ser Leu Met Lyt ^ rg Pro Pro Cly Pht Ser Pro Pht Ar^Str Str Arg lit Cly Clu lit 
ATT lAC CCT ACT CTC AAC TCT CAA CCA CTC CCA ATC ATC TCA CTC ATC AAA ACC CCT CCA CCT TTT T a CCT TTC CCA TCA TCA CCA ATA CCC CAA ATA 
11*0 1150 1160 1170 1180 1190 1200 1210 1220 1230 
400 410 420 427 
Lyt Clu Clu Thr Thr Ser Hit Leu Arg Ser Cyt Clu Tyr Lyt Cly Arg Pro Pro Lyt Alt Cly Alt Clu Pro Alt Ser Clu Arg Clu Vtl Ser STOP 
AAA CAA CAA ACA ACT ACT CAC CTA ACC TCC TCC CAC TAC AAC CCT CCA CCC CCA AAC CCA CCC CCA CAC CCA CCA TCT fiAC ACC CAC CTC TCT TCA CCA 
1240 1250 1260 1270 1280 1290 1300 1310 1320 1330 
ATC CCC AGA ATC TTC ACT CCA U X ACA TAC CCC CAA CCA CCT CTC CCA CCA ACC TTC ACA CCA ACC ACA ACA ACA AAC ATC CCA TAC AAT TTA AAT ACA 
1340 1350 1360 1370 1380 1390 1400 1410 1420 1430 
C A A CAA T C C C A T T T T A T C A C T C T C C C T C T C C C T C A A A T A A A C A T C A C T C T T C A T C T T C A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A AA , , 
1440 1450 1460 1470 1480 1490 1500 1510 1520 1529 
F i g . A Comple te nucleol ide sct^ucnce of ihe c D N A insert in XHTPI-1529 . T h e predicted a m i n o acid sequence is shown s ta r t ing with a 
melhionine residue that is encoded by the first A T G codon following a s top codon ( T A G ) in the s a m e reading f r a m e . T h e proposed cleavage 
site by signal peptidase is shown by a dot ted a r row. Potent ial c a r b o h y d r a t e binding sites to Asn residues a re shown by solid d i amonds . The 
solid heavy arrows show the sites c l tavoJ by liallik.rcin to release bradyWinin, a vasoactive nonapcptide. The boxed sequences indicate the proposed 
reactive sites of the inhibitor . The polyadenyla i ion or processing sequence of A A T A A A is shown by a bar . 
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Stoichiometry 
Salvesen et al (62) calculated 2:1 (enzyme : 
inhibitor) stoichiometry. Nevertheless, the results of 
Gounaris et al (43) pointed to 1:1 stoichiometry. The 
reason for this discrepancy is unclear. However, when the 
inhibitory activities of various derivatives of high and 
low molecular weight TPl was carried out by Higashiyama et 
al (63) highest inhibition capacity (74%) with a full 
binding ratio (2.0) was observed when only heavy chain 
alone was taken which corresponds to a stoichiometry of 
2:1 (enzyme : inhibitor). This result indicates that 
light chain and fragment 1, 2 moities of TPI molecule 
interfere with a inhibitory activity of heavy chain by 
steric hindrance. 
Nature of the interaction 
It was originally thought that the inhibition of 
thiol proteinases by TPI might involve the formation of a 
disulphide bond between the active site thiol and the 
inhibitor. The evidence was indirect, depending upon the 
effects of some thiol blocking reagents on the interaction 
(64, 65). It is now clear that no disulphide bond is 
formed, because complexes dissociate when unreduced and 
denatured (43). Carboxymethylation of enzyme and/or 
inhibitor does not prevent complex formation (66). Hence 
the interaction of the TPI with thiol proteinases is 
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reversible, competitive with substrate, non-covalent with 
no detectable formation or cleavage of covalent bonds. 
Ohkubo et al (59) isolated a human cDNA for a2-TPI and 
found a striking similarity (overall homology 74%) in the 
sequence of a2-TPI and bovine low molecular weight 
kininogen. 
KININOGEN 
Kininogens are the members of cystatin superfamily 
which consist of three families of more closely related 
proteins having about half of their amino acid residues in 
common, Fig. 1. 
Family 1 
It consisted of about 110 amino acid residues 
(Mr 11,000) with no disulphide bonds or carbohydrate 
groups e.g. cystatin A and B from human skin (26, 67, 68), 
These proteins are also known as stefins (69). They may 
contain cysteine residues which play an important role in 
biological activity (70). 
Family 2 
Inhibitors of this family are made up of 115 amino 
acid residues (Mr 13,000) and contain two disulphide bonds 
towards the carboxyl terminus e.g. chicken egg white 
(71, 72), cystatin C from cerebrospinal fluid (73), urine 
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Fig. 1 A diagrammatic representation of the chain 
structures of proteins in the cystatin superfamily. 
The structure indicated for the kininogens is that 
of L-and T-kininogens; H-kininogens have a longer 
carboxyterminal extension . There is thought to be 
an additional disulphide link from segment 1 to the 
kinin segment. The symbol 4 marks potential sites 
for the attachment of the carbohydrate side chains. 
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(74), normal serum and seminal plasma (75), cystatin S 
(76) and at lower concentration in other fluids including 
blood plasma (77). 
Family 3 
Family 3 of the cystatin superfamily, consists of 
kininogens. Each of these contain three family 2 like 
domains that have clearly resulted from two duplications 
of genetic material. In these composite sequences, 
comprising about 355 amino acid residues in total, there 
are additional disulphide bonds and the molecules are also 
glycosylated. At their carboxyl termini, the kininogens 
have an additional polypeptide unrelated to the low Mr 
cystatins containing the bradykinin sequence that can be 
released by the action of kallikrein (78, 79). 
Kininogens are the precursor molecules for the 
vasodilator kinin peptides e.g. bradykinin, kallidin and 
methionyl kallidin (80, 81). Kininogens were demonstrated 
to be potent inhibitors of thiol proteinases such as papain 
calpain and cathepsins (59, 82, 83). Key functions of the 
• 
kininogens effected via kinin are smooth muscle 
contraction, induction of hypotension and increase of 
vascular permeability (84). Kininogens also play a 
functional role in the initiation of blood coagulation 
(85, 86), blood pressure regulation (87) and the control of 
cellular glucose uptake (88), however a consistent view of 
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its physiological function is still lacking. All 
kininogens have same basic structure a heavy chain of some 
50-60 KD, the kinin segment in the core part of the 
molecule, and the light chain of variable length at the 
carboxy terminus (89-93). High molecular weight kininogen 
(HMWK) has a large light chain of 45-58 KD which harbors 
a unique histidine rich region known to facilitate the 
binding of the molecule to subendothelial surface (94). 
In addition, the HMWK light chain contains the binding 
site (s) for prekallikrein and factor XI. Low molecular 
weight kininogen (LMWK) has a rudimentary light chain of 
4-5 KD that lacks the segments critical for contact 
activation or proenzyme binding (81, 95, 96). 
An interesting feature of purified human kininogens 
is their tendency to form oligomers (Table 3). High 
molecular weight kininogen forms dimers, tetramers and 
hexamers, while self association of low molecular weight 
kininogen is even more pronounced as dimers upto decamers 
are found. Oligomerisation is completely reversible in 
the presence of dissociating agents e.g. sodium 
dodecylsulphate. Gel filtration experiments with 
kininogen fragments demonstrate that the isolated heavy 
chain from HMWK is eluted with an apparent Mr of 130,000 
i.e. it dimerizes, whereas the corresponding light chain 
does not (apparent Mr 65,000). Hence, oligomerisation of 
human kininogens is mediated by the heavy chain common to 
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Table - 3 
MOLECULAR WEIGHTS OF KININOGEN OLIGOMERS AS DETERMINED BY 
GRADIENT POLYACRYLAMIDE ELECTROPHORESIS IN THE ABSENCE OF 
DISSOCIATING AGENTS 
Oligomer LMWK (Found) (Expected)^ HMWK 
Monomer 78,000 68,000 140,000 
Dimer 185,000 136,000 350,000 
Tetramer 305,000 272,000 540,000 
Hexamer 450,000 408,000 n.d. 
Octamer 580,000 544,000 n.d. 
Decamer 780,000 680,000 n.d. 
n.d. = not detected 
a Calculated from an Mr of 68,000 for low molecular weight 
Kininogen determined by SDS-PAGE (4-30%). 
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both types of kininogens (97). 
Occurrence of kininogen oligomers in plasma seems 
unlikely as HMW kininogen is known to form binary 
complexes with blood clotting factors (98). Removal of 
these associated proteins during purification procedure 
may unshield the corresponding binding sites of HMW 
kininogen and thus facilitate self aggregation of the 
purified protein. Appearance of multiple forms of human 
kininogens (99) is most probably due to kininogen 
oligomers rather than to kininogen precursor molecules. 
Antibodies raised against HMWK have previously shown 
that LMWK cross reacts with apparent complete identity 
with HMWK using such antibodies (45). Other immunological 
studies (100, 101) indicated that the two kininogens share 
a large number of determinants (102) using antiserum 
against the isolated heavy chain of bovine HMWK which 
showed apparent complete identity with the isolated heavy 
chain of both bovine HMWK and LMWK. These results 
indicate that the heavy chain of HMW and LMW kininogen 
extensively share identical immunological determinants. 
Moreover, the immunological determinants of the light 
chain of human HMWK is unique to this molecule and are not 
apparent in LMW kininogen. Procoagulant property of HMWK 
is inhibited by the y-globulin fraction of the anti-light 
chain antiserum. Alkylated light chain and heavy chain 
isolated from the human (103, 104) and bovine (105, 106) 
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kinin free HMWK when analysed for the procoagulant 
activity indicated that only the alkylated light chain 
retains the activity. Human LMWK does not exhibit 
procoagulant activity (107). 
Kininogens are strong inhibitors of thiol proteinases, 
probably they are the most abundant inhibitors of thiol 
proteinases in plasma (total kininogen concentration 
210 mg/litre) (108). Evidence from immunological, 
enzymological and sequence data (83) predict that human 
plasma kininogens are identical with a-thiol proteinase 
inhibitors. Ohkubo et al (59) showed by immunoprecipita-
tion that human a2-TPI and human low molecular weight 
kininogens to be identical. Later on Muller (83) and 
Sueyoshi (82) proved that human high molecular weight 
kininogen and low molecular weight kininogen are in fact 
identical to the high and low molecular weight thiol 
proteinase inhibitors of human plasma and they also showed 
that kininogen purified as kininogen rather than by the 
special methods that had been developed for a-thiol 
proteinase inhibitor, are potent inhibitors of thiol 
proteinases. Immunological cross-reactivity of antiserum 
against high and LMW kininogen with HMW kininogen, low-Mr 
kininogen and LMW-a TPI yielded a pattern of partial and 
fused precipitin lines respectively on immunodiffusion 
test. This indicates that anti HMW kininogen-directed 
IgGs recognize both epitopes common to HMW kininogen and 
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LMW-aTPI as well as antigenic sites unique for HMW 
kininogen, whereas with anti-LMW kininogen directed 
antibodies, L M W - a T P I and the two kininogens share 
antigenic sites recognized by it. Immunoprinting revealed 
that monoclonal antibodies directed against the heavy 
chain portion of the human HMW kininogen also recognized 
human LMW-aTPI. Since both kininogens also inhibit thiol 
proteinases with inhibition constants given in Table 4 
reveal that both sets have ki values in the same order of 
magnitude also stress the similarity, if not identity of 
the aTPIs and the kininogens. To further evaluate (83) 
LMW-aTPI was subjected to limited proteolysis by tissue 
kallikrein. Lys-bradykinin was quantitated by radio-
immunoassay which came out to be 4% of the total 
releasable kinin. When amino acid sequence of LMW-TPI was 
compared with those of low molecular weight kininogen, it 
was found to be identical. Similarly the amino acid 
sequence of high molecular weight thiol proteinase 
inhibitor is identical to that of high molecular weight 
kininogen (83). 
For the determination of ki values, tight binding 
methods of analysis were used such as those of Henderson 
(109), Baici and Gyger-Marazzi (110) and Nicklin and 
Barrett (111). Some of the reported ki values with 
different thiol proteinases are reported in Table 4. 
Inhibition of cathepsin B tends to be weaker than that of 
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papain, cathepsin H and L. 
Biological Aspects 
Very little can be said with certainty about the 
physiological functions of the proteinase inhibitors of 
the cystatin superfamily. In general/ present knowledge 
of proteinases and their endogenous inhibitors at the 
molecular level is much more detailed than of the 
physiological functions of either the enzymes or the 
inhibitors. Thiol proteinase .inhibitors found in serum 
(28, 41, 42, 112, 113) differ from the tissue inhibitor in 
enzymological and immunological properties (114-116). In 
.contrast to the thiol proteinases, which are present in 
lysosomes, the thiol proteinase inhibitor is found 
exclusively in the cytosol fraction (116). Thus the 
inhibitor probably masks the activities of lysosomal thiol 
proteinases when the lysosomal membranes are broken during 
tissue homogenization. 
Thiol proteinases are thought to act mainly within 
cells (117) and in tissue spaces (118) and it is in these 
extravascular compartments that TPIs may be supposed to 
intervene to prevent tissue damage. Because of their 
lower Mr values than that of TPIs diffuse more easily 
from blood vessels and could therefore be the preferential 
inhibitors of these proteinases extravascularly. This is 
supported by the analysis of pleural fluid from which 
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a2-TPI was prepared. a^l^ is 5 fold less concentrated in 
this fluid than in plasma, whereas, a2-TPI is at the same 
concentration in both fluids. On the other hand, and 
unlike its homologue in rat serum (119), human a^-TPI was 
not found to be an acute phase reactant. Proteinase 
inhibitors are very useful both in vitro and in vivo for 
studies on the mechanism and control of intracellular 
protein catabolism. Addition of proteinase inhibitors to 
cell or their injection in vivo not only inhibits 
lysosomal proteinase activities, but also causes formation 
of autophagic vacuoles (120) and induces synthesis of 
hemoglobin hydrolyzing thiol proteinase (121, 122). 
Increase of autophagic vacuoles in cells by treatment with 
leupeptin is responsible for inhibition of lysosomal thiol 
proteinase activities with a consequent decrease of 
protein degradation. Recent studies indicated that the 
rate of sequestration of substrate proteins into the 
autophagic vacuoles may be the rate limiting step in the 
process of protein degradation, and that lysosomal 
proteinase, especially thiol proteinase, exist in excess 
and may not be the rate-limiting step. Greater 
inhibition by proteinase inhibitors of exogenous protein 
degradation than of endogenous protein breakdown has been 
reported (123). The regulation of TPI in response to 
different diseased states is a complex area, but one with 
broad implication (124). Sasaki et al (58) have suggested 
that inhibition of calpain in the blood may be mediated 
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predominantly by aTPI. This could be important in view of 
the marked effects of calpain on platelet function 
reported by Yoshida et al (125). 
Machleidt et al (126) calculated that TPI could 
provide complete control of the action of extracellular 
cathepsin L, incomplete control of cathepsin H and very 
little control of cathepsin B. 
All of the known human hereditary deficiencies of 
TPIs involve essentially complete lack of high molecular 
weight TPI, with levels of low molecular weight TPI 
ranging between 0 and 100% of normal (127). Low molecular 
weight TPI is as good an inhibitor of thiol proteinases as 
high molecular weight TPI, only the few cases of 
deficiency of both TPIs would offer the prospect of 
clearly demonstrating a physiological function of thiol 
proteinase inhibition by the TPIs, and there has been no 
indication of this as yet. 
Therefore, keeping in view of the lack of information 
regarding their specificity, mode of interaction, number 
of reactive sites and mechanism of inhibition and the 
importance of thiol proteinase inhibitor, isolation of a 
pure preparation of this inhibitor is an essential 
pre-requisite. A review of the literature shows that 
purification of human low molecular weight thiol 
proteinase inhibitor reported by various laboratories 
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(48-51) requires many steps and the recovery from plasma 
is very low. 
SCOPE OF THIS THESIS 
We have developed a simple three step purification 
method avoiding multi step purification including affinity 
chromatography for human'plasma thiol proteinase inhibitor 
with good yield and fold purification. 
Previously (48, 59, 63) workers have reported the 
presence of high and low molecular weight TPI in human 
plasma. In this study we have obtained low molecular 
weight TPI of 70,000 which is closer to that reported by 
Ryley (41) and a high molecular weight TPI of 1,56, 000 
close to one reported by Nakayasu et al (128). In 
addition to these we have also obtained two additional 
TPI's of molecular weight 1,95,000 and 4,97,000 
respectively. Thus in total we have obtained four 
multimolecular forms of TPI in human plasma. 
We have centered our studies on and 
TPI since these were isolated to a functionally pure state 
while the Ilnd TPI was heterogeneous. Our aim in this 
study was to characterize the two additional multirrolecular 
forms and then to compare the properties of these 
inhibitors with 1st inhibitor. Therefore, these three 
inhibitors were characterized on the basis of several 
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physio-chemical properties. The results thus obtained are 
given in this thesis. 
e X P E R X M E M T f l L 
26 
MATERIALS 
Chemicals used for the present studies were obtained 
from the sources indicated against their names. 
S.No. Chemical 
1. Acrylamide 
2. Agarose 
3. Ammonium sulphate 
4. Benzoyl-DL-Arginine-p-
nitroaniline 
5. Blue dextran 
6. Bovine serum albumin 
7. Bromophenol blue 
8. Casein 
9. Coomassie brilliant 
blue R-250 
10. Cathepsin B 
11. Chymotrypsinogen 
12. Cysteine hydrochloride 
13. Cytochrome C 
14. Diethylaminoethyl 
cellulose 
15. Dimethyl sulphoxide 
16. Disodium monophosphate 
17. Ethylenediaminetetra-acetic 
acid 
18. Folin phenol reagent 
Source 
Sigma Chemical Co., U.S.A. 
Sigma Chemical Co., U.S.A. 
E. Merck Pvt. Ltd., India 
Sigma Chemical Co., U.S.A. 
Sigma Chemical Co., U.S.A. 
Sigma Chemical Co., U.S.A. 
B.D.H., England 
Difco Lab., U.S.A. 
Sigma Chemical Co., U.S.A. 
Sigma Chemical Co., U.S.A. 
Sigma Chemical Co., U.S.A. 
John Baker Inc., U.S.A. 
Sigma Chemical Co., U.S.A. 
Reanal, Hungary 
Qualigens Fine Chemicals., 
India 
Qualigens Fine Chemicals., 
India 
S.D. Fine Chem. Pvt. Ltd., 
India 
Qualigens Fine Chemicals., 
India 
27 
19. Freund's complete adjuvant 
20. Glycine 
21. Hydrochloric acid 
22. N.N'-Methylenebisacrylamide 
23. Ovalbumin 
24. Papain 
25. Pepsinogen 
26. Phenol 
27. p-Nitrophenyl phosphate 
28. Rabbit anti-rabbit IgG 
alkaline phosphatase 
conjugate 
29. Sephadex G-200 
30. Sodium azide 
31. Sodium bicarbonate 
32. Sodium carbonate 
33. Sodium chloride 
34. Sodium diphosphate 
35. Sodium hydroxide 
36. Sodium lauryl sulphate 
37. Sucrose 
38. Sulphuric acid 
39. Trichloroacetic acid 
40. Tris (hydroxymethyl) 
amino methane 
Difco Lab., U.S.A. 
Qualigens Fine Chemicals., 
India 
Qualigens Fine ChemicalSv 
India 
B.D.H., India 
Sigma Chemical Co., U.S.A. 
Sigma Chemical Co., U.S.A. 
Sigma Chemical Co., U.S.A. 
Loba Chemie., India 
Sigma Chemical Co., U.S.A. 
Sigma Chemical Co., U.S.A. 
Pharmacia Fine Chemicals*, 
Sweden 
B.D.H., India 
B.D.H., India 
B.D.H., India 
Qualigens Fine Chemicals., 
India 
B.D.H., India 
B.D.H., India 
Loba Chemie, India 
B.D.H., India 
Qualigens Fine Chemicals., 
India 
Qualigens Fine Chemicals., 
India 
Sigma Chemical Co., U.S.A. 
41. Trypsin Sigma Chemical Co., U.S.A. 
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METHODS 
1 . Blood; Outdated human blood obtained from the local 
Medical College or fresh blood donated by apparently 
healthy volunteers was obtained. Plasma was separated by 
centrifugation in Remi C-24 cooling centrifuge for_ 10 
minutes. 
2. COLUMN CHROMATOGRAPHY 
(A) Sephadex Column Chromatography 
A column of Sephadex G-200 was prepared as 
recommended by Peterson and Sober (130) at room 
temperature. Sephadex G-200 was allowed to swell in a 
suitable amount of distilled water for 5 hours in a 
boiling water bath. A previously cleaned glass column was 
mounted vertically and glass wool plugged alongwith glass 
beads at the bottom of the column. The column was filled 
to one third of its length with the operating buffer. The 
deaerated gel slurry was then gently poured into the 
column with the help of a glass rod. The column was left 
standing overnight. Flow rate was subsequently increased 
gradually with the help of stop cock. After accomplishing 
a constant rate of flow higher than required for final 
elution, the column was adjusted to the required flow 
rate. The column was thoroughly washed with two bed 
volumes of operating buffer (0.01 M sodium - phosphate 
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buffer, pH 8.0 with 0.15 M sodium chloride). In order to 
determine the uniform packing and void volume (V^) of the 
column, 2.0 ml of 2% (W/V) blue dextran was passed through 
the column. The buffer was carefully removed from the 
surface and protein sample applied. The volume of blue 
dextran or protein solution applied on the column was not 
more than 2 - 3% of the total bed volume of the column. 
(B) DEAE-Cellulose Chromatography 
Appropriate amount of DEAE-cellulose was suspended 
with 15 volumes of 0.5 N HCl for half an hour and washed 
in a Buchner funnel. The washing was continued till the 
pH of the filtrate was approximately 7.0. The exchanger 
was then treated with 15 volumes of 0.5 N sodium hydroxide 
for half an hour and the washing continued till the pH of 
the filtrate approached neutrality. The DEAE-cellulose 
was then resuspended in operating buffer to get a 
homogenous slurry. This slurry was poured on a vertically 
mounted glass column plugged with glass wool with the help 
of a glass rod. The column was left standing for one 
hour. Flow rate was subsequently increased gradually with 
the help of stop-cock. After accomplishing a constant 
rate of flow higher than required for final elution, the 
column was adjusted to the required flow rate. The column 
was then equilibrated with excess of the operating buffer 
till the pH of the effluent was identical to that of the 
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eluting buffer. Elution was performed with a linear 
gradient (0.0 - 0.3 M) of sodium chloride in 0.01 M sodium 
phosphate buffer, pH 8.0. 3.0 ml fractions were collected 
and assayed for inhibitory activity and protein 
concentration. NaCl concentration in various fractions 
were determined by conductivity measurements. 
3. SLAB GEL ELECTROPHORESIS 
(A) Polyacrylamide Gel Electrophoresis 
PAGE was performed essentially, according to the 
method of Laemmli (131) using slab gel apparatus 
manufactured by Atto Co., Japan. Concentrated stock 
solutions were mixed in appropriate order and proportions 
to give a final concentration of 5% acrylamide. It was 
then poured into the mold formed by two glass plates 
(7x9 cm) separated by 1.5 mm thick spacer. Bubbles and 
leaks were avoided. A comb providing a template for 12 
sample wells were inserted into the stacking gel solution 
before polymerization began. The polymerization was 
complete in about 2 hours. The comb was removed and the 
wells thus formed were washed and overlaid with reservoir 
buffer. The samples for electrophoresis were prepared by 
mixing protein samples containing 25 P-g with equal volume 
of sample buffer containing bromophenol blue and 10% (W/V) 
sucrose were applied to the wells of the slab gel. 
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Electrophoresis was carried out at 50 V for approximately 
4 hours in Tris-Glycine reservoir buffer (0.0248 M Tris & 
0.192.M Glycine), pH 8.3 till the tracking dye reached the 
bottom of the gel. After completion of the electro-
phoresis, the gels were immediately subjected to fixation 
and staining with coomassie brilliant blue. The gels were 
treated with staining and destaining solutions in the 
following order: 
1. 0.1% coomassie blue R-250 in 25% isopropanol and 10% 
glacial acetic acid for 2 - 4 hours; 
2. destaining of the gels for several hours with 10% 
glacial acetic acid and 20% methanol until the blue 
background became clear. 
(B) SDS-Polyacrylamide Gel Electrophoresis 
SDS-PAGE was performed essentially according to the 
method of Laemmli (131) using a mini slab gel apparatus 
manufactured by Atto Co., Japan. It was used for the 
determination of subunit structure of the purified 
inhibitor. The proteins were denatured by treating 25 ug 
of protein in 0.01 M sodium - phosphate buffer, pH 8.0 
with 3% SDS and reduced with 5% of 2-mercaptoethanol, few 
drops of 10% (W/V) sucrose solution and 0.05% (W/V) 
bromophenol blue dye were added to the protein solution, 
which was then kept for 5 minutes at 100°C and then it was 
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brought to room temperature. Protein solution were added 
on top of the freshly prepared 7.5% gel containing 0.62% 
acrylamide and bis acrylamide, 0.02% SDS, 0.005% (W/V) 
ammonium persulphate, 0.08% V/V N, N, N', N' 
tetramethylenediamine and 1.5 M Tris - HCl buffer, pH 8.8. 
Electrophoresis was carried out for 4 hours in 
Tris-Glycine reservoir buffer (0.0248 M Tris and 0.192 M 
Glycine), pH 8.3 containing 1% (W/V) SDS by passing a 
current of 50 V. The gels were then stained with 
coomassie blue for 1 hour and destained mechanically in a 
mixture of 20% (V/V) methanol and 10% (V/V) glacial acetic 
acid. 
4. COLORIMETRIC ANALYSIS 
(A) Protein Estimation 
Determination of protein concentration for routine 
experiments such as monitoring of chromatographic columns, 
the protein concentration was determined by the method of 
Lowry et al (132) using Folin-phenol (133). Suitable 
aliquots of protein solutions were diluted to 1.0 ml with 
distilled water. To this was added 5.0 ml of freshly 
prepared copper reagent (prepared by mixing 1% (W/V) 
copper sulphate, 2% (W/V) sodium potassium tartarate and 
2% (W/V) sodium carbonate in the ratio of 1:1:100 in 0.1 N 
sodium hydroxide). After incubation at room temperature 
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for 10 minutes, 0.5 ml of 1 N Folin-phenol reagent was 
added and the tubes were instantly vortexed. Absorbance 
of the blue colour was measured after 30 minutes at 660 nm 
against a reagent blank in a Bausch and Lomb spectronic 
20 spectrophotometer. 
(B) Determination of Proteinase Activity 
Proteinase activity was determined using casein as 
substrate by the method of Kunitz (134) with slight 
modification. About 40 pg of papain was taken in 0.4 ml 
of 0.01 M sodium-phosphate buffer pH 8.0 containing 0.05 M 
cysteine and 0.02 M EDTA was incubated for 5 minutes at 
37°C. The volume of the reaction mixture was made 1.0 ml 
by the same buffer and then 1.0 ml of 2% (W/V) of casein 
was added and reincubated for 30 minutes at 37°C. The 
reaction was stopped by the addition of 1.0 ml of 10% 
(W/V) of trichloroacetic acid. After 15 minutes, tubes 
were centrifuged at 3000 r.p.m. for 10 minutes. An 
appropriate amount of aliquot were developed by Lowry's 
procedure (132). The control was prepared in identical 
manner except that casein was added 30 minutes after the 
addition of trichloroacetic acid and the blue colour was 
read at 660 nm. 
(C) Thiol Proteinase Inhibitor Assay 
(i) Caseinolytic method 
Thiol proteinase inhibitory activity was determined 
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by measuring inhibition to the activity of papain. To 
0.2 ml of papain (40 p.q) , 0.2 ml of activating agent 
(0.05 M cysteine and 0.02 M EDTA, pH 8.0) was added and 
incubated for 5 minutes at 37°C. An appropriate amount of 
fraction containing thiol proteinase inhibitor was added 
and the volume of the reaction mixture was made 1.0 ml 
with 0.01 M sodium phosphate buffer, pH 8.0 and it was 
preincubated for 30 minutes at 37°C. To this 1.0 ml of 
reaction mixture, 1.0 ml of 2% (W/V) casein was added and 
then again incubated for 30 minutes at 37°C. Reaction is 
stopped by the addition of 1.0 ml of 10% (W/V) trichloro-
acetic acid. After standing for an additional 15 minutes, 
tubes were centrifuged at 3000 r.p.m. for 10 minutes. An 
appropriate amount of aliquot from each test tube was 
developed by Folin-phenol reagent and the intensity of the 
blue colour was read at 660 nm against the reagent blank. 
The readings were corrected for blank solutions in which 
the reaction was stopped by 1.0 ml of 10% (W/V) 
trichloroacetic acid prior to the addition of 1. 0 ml of 2% 
(W/V) casein. 
(ii) Amidase method for papain 
0.2 ml of papain (22/ag/0.2 ml) is first activated by 
5 mM cysteine and 2 mM EDTA pH 8.0 for 10 minutes at 37°C. 
Then appropriate amount of inhibitor is added and the 
volume of the reaction mixture is made 1.0 ml with 10 mM 
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sodium phosphate buffer, pH 8.0. This reaction mixture is 
then incubated for 30 minutes at 37°C. After this 
incubation 1.0 ml of 2 mM BAPNA solution is added and 
again it is incubated for 60 min at 37°C. The reaction is 
terminated by the addition of 1.0 ml of C.30 M acetic 
acid. Suitable blank is made by adding acetic acid prior 
to the addition of BAPNA. 
(iii) Aniidase assay for cathepsin B 
22 /ag/0.1 ml of cathepsin B is activated by 5 mM 
cysteine and 2 mM EDTA pH 6.0 for 10 min at 37°C. Then 
appropriate amount of inhibitor is added and the volume is 
made 1.0 ml with lOmtl sodium citrate buffer, pH 6.0 and is 
incubated for 30 min at 37°C. 1.0 ml of 2 mM BAPNA 
solution is added and then again incubated for 60 min at 
37°C. Reaction is stopped by the addition of 1.0 ml of 
0.30 M acetic acid. Blank is made by adding acetic acid 
first before adding BAPNA. 
(iv) Amidase assay for trypsin 
To 20 p.q/Q.2 ml of trypsin, an appropriate amount of 
inhibitor is added and the volume is made 1.0 ml with 
10 mM phosphate buffer, pH 8.0. This reaction mixture is 
incubated for 30 min at 37°C. 1.0 ml of 2 mM BAPNA 
solution is added and again it is incubated for 60 min at 
37°C. The reaction is terminated by the addition of 
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1.0 ml of 0.30 M acetic acid. Suitable blank is made by 
adding acetic acid prior to the addition of BAPNA. 
(D) Carbohydrate Estimation 
The method used was that described by Dubois et al 
(135) using glucose for standard curve. To a 2.0 ml of 
sample containing appropriate quantity of protein in 10 mM 
phosphate buffer pH 8.0, 0.05 ml of 80% phenol solution 
was added. Five ml of conc. H2S0^ was subsequently added 
rapidly keeping the stream of acid directed against the 
liquid surface in order to get a good mixing. The tubes 
were allowed to stand for 10 min. They were then vortexed 
and further incubated at 30°C for 20 min. The absorbance 
of the yellow colour developed was measured at 490 nm 
against the blank. 
5. Immunological Studies 
(A) Preparation of Antibodies 
Antibodies against smallest molecular weight 
inhibitor (Mr - 70,000) were raised in healthy albino 
rabbit. An emulsion of 0.5 ml of inhibitor (168.8 jag/ 
0.5 ml) and 0.5 ml of Freund' s complete adjuvant was 
injected intramuscularly. Such treatment was again given 
in the third and fourth weeks. Animals were bled after 
the fifth week and the blood was allowed to coagulate for 
4 h at 4°C. Antisera were collected from the coagulated 
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blood and stored at -10°C. 
(B) Immunodiffusion 
The precipitation reaction in agarose gels was 
performed according to the method of Tan and Kunkel (136). 
One percent molten agarose in 0.9 M NaCl containing 0.1% 
sodium azide was poured on the slides and allowed to 
harden at room temperature. Required number of wells were 
cut from the agarose and the slides were stored at 4°C. 
5-10 /il of suitably diluted antisera were added in the 
central well and the antigens in the wells around the 
central well. 
(C) Enzyme Linked Immunosorbent Assay (ELISA) 
INHIBITION ELISA 
Buffers and substrate 
(1) Tris buffer saline (TBS), pH 7.4, 10 mM Tris, 150 mM 
NaCl pH 7.4 containing 0.02% sodium azide as 
preservative. 
(2) Tris buffer saline Tween-20 (TBS-T) , pH 7.4, 2.4 gm 
Tris (20 mM), 8.4 gm sodium chloride, 200 mg 
potassium chloride and 500 pi Tween-20 was dissolved 
in 800 ml distilled water, pH adjusted to 7.4 with 
IN HCl. The volume was made to 1 litre. 
(3) Bicarbonate buffer, pH 9.5, 15 mM sodium carbonate, 
35 mM sodium bicarbonate, pH 9.5 containing 0.02% 
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sodium azide as preservative. 
(4) Substrate, 500 /ag p-nitrophenyl phosphate per ml in 
bicarbonate buffer. 
Procedure 
The specificity of ELISA were ascertained 
by inhibition experiments (137). Polystyrene 
microtiter plates were incubated with 100 /al of 1st 
inhibitor (0.5 ;ag/100 ^1) for 2 h at room temperature and 
then overnight at 4°C. The plates were washed three times 
with TBS, pH 7.4 containing Tween-20. 
The unoccupied sites were saturated by incubation 
with 150 ;ul/well of 1.5% BSA in TBS for 6 h at room 
temperature. Immune complex is made by adding varying 
amounts of inhibitors (0.01-50 ;ag/ml) with a constant 
amount of antibodies (90 /ig/100 ;ul). The mixture was 
incubated for two hours at room temperature. Before 
pipetting immune complex to the wells, plates were washed 
with TBS-T tv/o to three times and then immune complex was 
coated J & Kej>t for 2 h at room temperature and then 
overnight at 4°C. Next day washeAthe plates with TBS-T 
thrice. Bound antibodies were assayed with an appropriate 
anti-rabbit alkaline phosphatase (1 : 9000 dil). 100 ul 
of it is coated in each well^^ Kept for 2 h at room 
temperature. Wash the plates with TBS-T five times and 
once with distilled water. Now add para-nitrophenyl 
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phosphate (50 /ag/100 /al) in each well and keep it for 
30 min at 37°C. Stop the reaction by adding 100 of 3 M 
NaOH in each well. The absorbance of each well was 
monitored at 410 nm. Results were expressed as percent 
inhibition : 
„ . , • • • J. • inhibited , , ^ n % inhibition = :—. ., . , ••. - 1 x 100 uninhibited 
6. Optical Measurements 
In the ultra-violet region, light absorption 
measurements were performed on PU-8800 UV absorption 
spectrophotometer (Pye Unicam). Fluorescence measurements 
were carried out on Shimadzu spectrofluorometer, model 
RF-540 using quartz cell of 1 cm path length. 
7. Photography 
Gels stained with coomassie brilliant blue R-250 
were photographed on ORWO under illumination. 
R C S U L T T S 
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1. Purification of Human Plasma Thiol Proteinase Inhibitors 
A) Ammonium Sulphate Fractionation 
Sufficient amount of ammonium sulphate was added to 
plasma to give a final concentration of 35% and the 
preparation left for 8 hours for protein precipitation. 
The precipitate obtained was discarded. The concentration 
of ammonium sulphate was then raised to 55% saturation in 
the supernatant and was kept again for 8 hours at 4°C for 
precipitation. The precipitate was collected by centrifu-
gation at ISOOOxg for 30 minutes in a Remi C-24 cooling 
centrifuge. Precipitate was then dissolved in 24 ml of 
lOml'l phosphate buffer, pH 8.0 and dialyzed three times 
against 50 volumes of the same buffer containing 0.15 M 
sodium chloride. 
B) Sephadex G-200 Gel Filtration 
The protein precipitated between 35-55% saturation of 
ammonium sulphate was applied on a column of Sephadex 
G-200 (2.7x50 cm) equilibrated with lOmM phosphate buffer, 
pH 8.0 containing 0.15 M sodium chloride. Fig. 2 
represents the elution profile of thiol proteinase 
inhibitory activity on Sephadex G-200 column. Fractions 
were analyzed for protein concentration and inhibitory 
activity using casein as substrate as described in the 
method. Proteins were eluted in three major peaks, while 
papain inhibitory activity was eluted as four significant 
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peaks (Fig. 2). Fractions showing inhibitory activity 
against papain were then pooled, concentrated and dialyzed 
against lOmM phosphate buffer, pH 8.0. In eight separate 
experiments the chromatographic profile shown in Fig. 2 
was found to be reproducible. Experiment with fresh blood 
also gave the similar profile in Sephadex G-150 column 
(Fig. 3). When plasma alone was subjected to Sephadex 
G-150 column chromatography, it also gave the identical 
elution profile (Fig. 4). 
C) DEAE-Cellulose Chromatography 
Separately pooled fraction corresponding to peaks 1-4 
as indicated in Fig. 2, were subsequently fractionated on 
DEAE-cellulose. The column was eluted with a linear 
gradient of 0 - 0.3 M sodium chloride in lOmM phosphate 
buffer, pH 8.0. Proteins of peak 1 (Fig. 2) were eluted 
between 0.24 - 0.27 M of sodium chloride (Fig. 5). Good 
correlation was obtained between the proteinase inhibitor 
activity and those of protein in various fractions. 
Proteins of peak 2 (Fig. 2) eluting between 0.21 - 0.26 M 
of sodium chloride (Fig. 6) had two protein peaks but 
thiol inhibitory activity appeared in the second protein 
peak. Peak 3 proteins (Fig. 2) eluted between 0.16-0.21 M 
of sodium chloride (Fig. 7) with inhibitory activity 
appearing after the protein peak between 0.12-0.14 M of 
sodium chloride. A small protein peak with insignificant 
Fig. 3 
Chromatography of Fresh Human Plasma on Sephadex 
G-150 
201.5 mg/3 ml of fresh human plasma (35-55% ammonium 
sulphate precipitated and dialysed protein) was 
applied on a column of Sephadex G-150 (3 x 83 cm) 
equilibrated with 0.01 M sodium phosphate buffer, 
pH 8.0 containing 0.15 M sodium chloride. The 
column was eluted in 5.0 ml fractions at a flow rate 
of 25 ml/hr. Each fraction was assayed for thiol 
proteinase inhibitory activity using casein as 
substrate and protein concentration. 
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Fig. 4 
Chromatography of Fresh Human Plasma on Sephadex 
G-150 
190 mg/3 ml of fresh human plasma was applied on a 
column of Sephadex G-150 (3 x 83 cm) equilibrated 
with 0.01 M sodium-phosphate buffer, pH 8.0 contain-
ing 0.15 M sodium chloride. The column was eluted 
in 5.0 ml fractions at a flow rate of 25 ml/hr. 
Each fraction was assayed for thiol proteinase 
inhibitory activity using casein as substrate and 
protein concentration. 
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Fig. 5 
Chromatography of Thiol Proteinase Inhibitor on 
DEAE-Cellulose Column 
The column (2.5 x 6 cm) was equilibrated with 0.01 M 
sodium-phosphate buffer, pH 8.0. 6.5 mg/5 ml of 
pooled peak 1 from Sephadex G-200 column was applied. 
The elution was performed in 3.0 ml fractions using 
a linear gradient of 0.0 M - 0.3 M sodium chloride 
at a flow rate of 37 ml/hr. Each fraction was 
assayed for thiol proteinase inhibitory activity 
using casein as substrate and protein concentration. 
( 0—O ) shows the continuous salt gradient. 
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Fig. 6 
Chromatography of Thiol Proteinase Inhibitor on 
DEAE-Cellulose Column 
The column (2.5 x 6 cm) was equilibrated with 0.01 M 
sodium-phosphate buffer, pH 8.0. 16.5 mg/10 ml of 
pooled peak 2 from Sephadex G-200 column was applied. 
The elution was performed in 3.0 ml fractions using 
a linear gradient of 0.0 - 0.3 M sodium chloride at 
a flow rate of 37 ml/hr. Each fraction was assayed 
for thiol proteinase inhibitory activity using 
casein as substrate and protein concentration. (O-O) 
shows the continuous salt gradient. 
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activity was also obtained. 
Peak 4 proteins (Fig. 2) weie. eluted between 
0.11-0.13 M of sodium chloride, its inhibitory activity 
coincided with the protein peak (Fig. 8). Extent of 
purification achieved and yield at various stages of 
purification of the thiol proteinase inhibitor are 
summarized in Table 5. Peak 1, 2, 3 and 4 thus purified 
had 346, 361, 1099 and 281 fold purification respectively 
with a yield of 11, 18, 10 and 10% respectively. 
2. Homogeneity 
Homogeneity of the four thiol proteinase inhibitors 
was determined by polyacrylamide gel electrophoresis as 
well as immunologically. Slab gel electrophoresis was 
performed in the absence of SDS. Ammonium sulphate 
fraction showed several bands in 5% acrylamide gel 
(Fig. 9-12, lanes A). After gel chromatography, the four 
inhibitory peaks thus obtained when electrophoresed again 
gave three to four bands indicating removal of some 
impurities (Fig. 9-12, lanes B) . On further purification 
by ion-exchange chromatography, the inhibitory fractions 
obtained gave single major protein bands for peaks 1, 3 
and 4 (Fig. 9, 11, 12, lanes C) indicating the removal of 
other proteins in the last purification step. Peak 2, 
however, showed charge heterogeneity with three bands and 
no efforts were made to characterize this inhibitor 
(Fig. 10, lane C). 
Fig. 8 
Chromatography of Thiol Proteinase Inhibitor on 
DEAE-Cellulose Column 
The column (2.5 x 6 cm) vs^ as equilibrated with 0.01 M 
sodium-phosphate buffer, pH 8.0. 7.84 mg/6.4 ml of 
pooled peak 4 from Sephadex G-200 column was applied. 
The elution was performed with a linear gradient of 
0.0 M - 0.2 M sodium chloride at a flow rate of 37 
ml/hr. 3.0 ml fractions were collected and each 
fraction v;as assayed for thiol proteinase inhibitory 
activity using casein as substrate and protein 
concentration, (o—o ) shows the continuous salt 
gradient. 
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Fig. 9 
Polyacrylamide Gel Electrophoresis of Peak 1 
The electrophoretic patterns of different 
preparations of peak 1 protein in 5% gel without SDS 
are shown. 25 pg of each preparation was electro-
phoresed on the slab gel at room temperature using a 
current of 50 V. 
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Crude inhibitor 
Sephadex G-200 fraction 
DEAE-cellulose fraction 
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Fig. 10 
Polyacrylamide Gel Electrophoresis of Peak 2 
The electrophoretic patterns of different prepara-
tions of peak 2 protein in 5% gel without SDS are 
shown. 25 /jg of each preparation was electrophoresed 
on the slab gel at room temperature using a current 
of 50 V. 
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Fig. 11 
Polyacrylamide Gel Electrophoresis of Peak 3 
The electrophoretic patterns of different prepara-
tions of peak 3 protein in 5% gel without SDS are 
shown. 25 jag of each preparation was electrophoresed 
on the slab gel at room temperature using a current 
of 50 V. 
Lan?e A : Crude inhibitor 
Lane B : Sephadex G-200 fraction 
Lane C : DEAE-cellulose fraction 
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Fig. 12 
Polyacrylamide Gel Electrophoresis of Peak 4 
The electrophoretic patterns of different prepara-
tions of peak 4 protein in 5% gel without SDS are 
shovvrn. 25 ^ g of each preparation was electrophoresed 
on the slab gel at room temperature using a current 
of 50 V. . 
Lane A : . Crude inhibitor 
Lane B : Sephadex G-200 fraction 
Lane C : DEAE-cellulose fraction 
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For immunological studies, rabbits were immunized 
with purified peak 1 protein in FCA. In immunodiffusion 
the rabbit immune sera exhibited single precipitin lines 
with all the four thiol proteinase inhibitors indicating 
the purity of the preparations (Fig. 13). 
Because of high sensitivity, inhibition ELISA was 
adapted for the detection of immunological cross 
reactivity, with the antibody against inhibitor-1. The 
technique involves the adsorption of purified thiol 
proteinase inhibitor-1 to the surface of microtiter plates 
and saturation of excess sites with BSA. The plates were 
then incubated with immune complex having fixed amount of 
antisera (9 0jug/100jul) and varying amounts of the 
inhibitors (0.01-50 ^ug/ml). The immune complex was 
detected by enzymatic reaction involving anti-rabbit IgG 
alkaline phosphatase conjugate. Measurement of enzyme 
activity was facilitated by the use of p-NPP as substrate. 
Immunized sera showed a strong positive reaction in ELISA 
with TPI-1 then in the decreasing order with TPI-3 and 
TPI-4 respectively (Fig. 14). 
3. Properties of the Thiol Proteinase Inhibitors 
(A) Molecular V-Veight 
The molecular weight of the purified inhibitors was 
determined by gel filtration on Sephadex G-200 as well as 
Fig. 13 
Immunodiffusion of Antiserum Prepared From Pure 
Thiol Proteinase Inhibitor-1 
Antisera were raised by injecting albino rabbits 
with purified antigen (TPI-1) (168.8 /jq/0.5 ml) 
alongwith 0.5 ml of EGA. Weekly injections were 
given and after four weeks the animals were bled and 
the cross-reactivity of the antigen with antiserum 
was tested by immunodiffusion as described in 
"Methods": 
A) TPI-1 
B) TPI-2 
C) TPI-3 
D) TPI-4 
E) Immunized serum. 

Fig. 14 
Inhibition ELISA of Thiol Proteinase Inhibitors 
0.01 - 50 /ig/ml of TPI-1, TPI-3 and TPI-4 were 
incubated with 90 ^g/0.1 ml of anti TPI-1. 
Experimental details are given in "Methods". 
{A ) TPI-1 
( o ) TPI-3 
( O ) TPI-4 
(iuj/5rr) dOiigiHNI 
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by PAGE performed in the presence of SDS. For gel 
filtration studies, 2 x 35.8 cm column was equilibrated 
with lOmM phosphate buffer, pH 8.0 containing 0.15 M 
sodium chloride. The column was calibrated with the 
markers BSA, ovalbumin, cC-chymotrypsinogen A and 
ribonuclease A. About 1 mg of purified inhibitors was 
chromatographed on the same column and the protein was 
eluted with the above buffer. 3.0 ml fraction were 
collected at a flow rate of 25 ml/hour. The elution 
profile of blue dextran, marker proteins and thiol 
proteinase inhibitors are shown in Fig. 15. The void 
volume (V^) was calculated by measuring the effluent peak 
position of blue dextran 2000 to be 44.3 ml. The first 
inhibitor (Fig. 5) was eluted as a single peak with 
elution volume of 76 ml. Thiol proteinase inhibitor-2, 
TPI-3 and TPI-4 (Fig. 6-8) exhibited an elution volume of 
62 ml, 58 ml and 41.5 ml respectively (Fig. 15). The 
total volume of the column V^, was found to be 112.3 ml. 
The data were processed using the following expressions:-
^av = (^e - - ^o) ••• (2) 
where K, is the distribution coefficient, K is the ci av 
available distribution coefficient and V^ is the inner 
volume, the latter was determined from water regain value 
Fig. 15 
Gel Filtration Profile of Standard Proteins and 
Thiol Proteinase Inhibitors on Sephadex G-200 
Column 
1.0 mg of each of the marker proteins and 1.0 mg of 
TPI-1, TPI-2, TPI-3 and TPI-4 were chromatographed 
on a 2.0 x 35.8 cm. column of Sephadex G-200, 
equilibrated with 0.01 M sodium-phosphate buffer, 
pH 8.0 containing 0.15 M sodium chloride. 3.0 ml 
fractions were collected at a flow rate of 25 ml/hr. 
Protein concentration were measured by the procedure 
of Lowry et al.(132): 
A) Blue dextran 
B) BSA 
C) Ovalbumin 
D) cK.-chymotrypsinogen A 
E) Ribonuclease A 
I) TPI-1 
II) TPI-2 
III) TPI-3 
IV) TPI-4 
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and the gram of dry Sephadex G-200 to be 81.5 ml. The 
ratio V /V of TPI-1, TPl-2, TPI-3 and TPI-4 was e o 
determined to be 1.717, 1.399, 1.31 and 0.936 respectively 
(see Table 6), A plot of V^/V^ versus log M, according to 
the procedure of Andrews (138) gave a straight line 
(Fig. 16). The molecular weight of TPI-1, TPI-2, TPI-3 
and TPI-4 computed from this plot came out to be 70794 , 
158489, 199526 and 501187 respectively. 
ANDREWS 
V^/V^ = 6.1838 - 0.9209 log M ... (3) 
According to equation (3) the molecular weight of TPI-1 
turned out to be 70871, 156959 for TPI-2,196079 for TPI-3 
and 499523 for TPI-4. 
The gel filtration data were also analyzed according 
to the method recommended by Porath (139). A linear plot 
between and M^^^ (see Table 6 and 7) was obtained by 
the method of least squares and the straight line obtained 
in Fig. 17 was found to give a value of 70752 for TPI-1, 
158516 for TPI-2, 199483 for TPI-3 and 501133 for TPI-4. 
PORATH 
M^/^ = 109.21 - 94.02 ... (4) d 
The value K^^/^ for TPI-1, TPI-2, TPI-3 and TPI-4 was 
measured to be 0.729, 0.601, 0.552 and 0.325 respectively 
which according to equation (4), would give a molecular 
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Fig. 16 
Determination of Molecular Weight of Thiol 
Proteinase Inhibitors 
The data from Fig. 15 v/as plotted as described by 
Andrews (138). 
using blue dextran. The ratio of elution volume 
Void volume (V ) was determined o 
(V^) to (V^) was plotted against the logarithm of 
molecular weights of the marker proteins: 
A) Ribonuclease A 
B) iK-Chymotrypsinogen A 
C) Ovalbumin 
D) BSA 
I) TPI-1 
II) TPI-2 
III) TPI-3 
IV) TPI-4 
(13,600) 
(26,100) 
(44,000) 
(69,000) 
Positions of the thiol proteinase inhibitors are 
indicated by an arrow. 
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Fig. 17 
Plot of Molecular Weight Against Distribution 
Coefficient 
The data obtained from Fig. 15 was plotted as 
described by Porath (139). Cube root of molecular 
v;eight was plotted against the cube root of 
distribution coefficient. 
A) Ribonuclease A 
B) pC-Chymotrypsinogen A 
C) Ovalbumin 
D) BSA. 
Thiol proteinase inhibitors are indicated by arrow: 
I) TPI-1 
II) TPI-2 
III) TPI-3 
IV) TPI-4 
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weight of 67268, 146385, 188237 and 486558 for the 
inhibitors respectively. The average of the molecular 
weight values computed by the help of Andrews (138) and 
Porath (139) plots and equations (3) and (4), turns out to 
be 70000, 155000, 195000 and 497000 for TPI-1, TPI-2, 
TPI-3 and TPI-4 respectively. 
(B) Stokes Radius 
As the elution volume of a protein from a gel 
filtration column correlates well with its stokes radius, 
r, the gel filtration data were plotted as recommended by 
Laurent and Killander (140). The available distribution 
coefficient, K was calculated by the help of equation 3. V 
(2) for marker proteins as well as for the four inhibitors 
and the values thus obtained are listed in Table 7. A 
1/2 plot of (-log K^ ) ' versus stokes radius was obtained by a V 
the method of least squares and the linear curve shown in 
Fig. 18 fits the equation:-
LAURENT AND KILLANDER 
("log K^^)^^^ = 0.1885 r - 0.0366 (5) 
For TPI-1, TPI-2, TPI-3 and TPI-4 (-log K was found 3 V 
to be 0.576 , 0.765 , 0 .834 and 1.18 respectively which 
would give a value of stokes radius 3.55, 4 .45, 4 .8 and 
6.5 nm respectively. 
Fig. 18 
Treatment .of Gel Filtration Data of Proteins 
According to Laurent and Killander 
The data obtained from Fig.15 was plotted as 
described by Laurent and Killander (140). The 
straight line was drawn by the method of least 
squares and fits the equation of Laurent and 
Killander 
(-log = 0.1885r - 0.03G6 
Marker proteins used are: 
A) Ribonuclease A 
B) oC -Chymotrypsinogen A 
C) Ovalbumin 
D) BSA 
Thiol proteinase inhibitors are indicated by arrow: 
I) TPI-1 
II) TPI-2 
III) TPI-3 
IV) TPI-4 
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The gel filtration data were also treated by the 
method recommended by Ackers (141) in the form of a plot 
of stokes radius and erfc"^ K^ (Fig. 19). A least square 
analysis of the values of stokes i-adius and erfc ^ K^ for 
marker proteins listed in Tables 6 and 7, yielded the 
straight line equation:-
erfc'^K, = 0.238 r - 0.182 ... (6) d 
The value of erfc~^K^ was determined to be 0»61, 0.88, 
0.97 and 1.35 for TPI-1, TPI-2, TPI-3 and TPI-4 respec-
tively, which according to equation (6) would correspond 
to a stokes radius of 3.3, 4.5, 4.85 and 6.45 nm 
respectively. Thus, the average value of the stokes 
radius for TPl-1, TPI-2, TPI-3 and TPI-4 calculated from 
equations (5) and (6) came out to be 3.43, 4.45, 4.82 and 
6.47 nm respectively. 
(C) Hydrodynamic Parameter 
The frictional ratio f/f^^ of TPI-1, TPI-2, TPI-3 and 
TPI-4 was computed from stokes radius (3.43, 4.45, 4.82 
and 6.47 nm respectively) by the help of equation:-
f/f^ = r/ ^ 3 ^ M\ 47^ N / (7) 
where M^ is the partial specific volume of the four 
inhibitors assumed to be 0.725 ml/g, M is the molecular 
Fig.19 
Plot of Stokes Radius Versus erfc"^ K, Obtained on g 
Sephadex G-200 
The data obtained from Fig. 15 was plotted as 
described by Ackers (141). The straight line was 
drawn by the method of least squares fits the 
equation of Ackers. 
erfc"^ K^ = 0.238r - 0.182 
A) Ribonuclease A 
B) <?C-Chymotrypsinogen A 
C) Ovalbumin 
D) BSA 
The value of stokes radius for the inhibitors are 
indicated by arrow. 
I) TPI-1 
II) TPI-2 
III) TPI-3 
IV) TPI-4 
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weight of protein inhibitors and N is the Avogadro's 
number (6.023 x 10^^). The frictional ratio of TPI-1 was 
calculated to be 1.3, 1.25 for TPI-2, 1.26 for TPI-3 and 
0.92 for TPI-4 with the help of the equation (7), 
The molecular weight of the inhibitors was also 
determined by SDS-PAGE at pH 8.3 in 7.5% gel, using the 
same marker proteins, as used in the calibration of 
Sephadex G-200 column described above. A plot of log M 
versus relative mobility R^ (Fig. 20) gave a straight 
line. From the R values of the inhibitors the molecular m 
v/eight of TPI-1 turned out to be 69 , 000 (Fig. 21) while 
for TPI-3 (Fig. 22) and TPI-4 (Fig. 23) it was 56000 and 
52000 respectively thus indicating that TPI-3 and TPI-4 
consists of four and ten subunits respectively, while 
TPI-1 is a single polypeptide chain. 
(D) Influence of pH 
The pH dependence of thiol proteinase inhibitors was 
tested between pH 3.0 - 9.0. Fig. 24 shows the effect of 
pH on the inhibitory activity of thiol proteinase 
inhibitors on papain using BAPNA as the substrate. Thiol 
proteinase inhibitor-1, TPI-3 and TPI-4 were labile belov/ 
pH 4.0. Exposure to buffer of pH 3.0 and 4.0 results in 
marked decrease in the inhibitory activity. However, the 
inhibitor was stable to pH between 5.0 - 9.0. 
Fig. 20 
Plot of Relative Mobility Versus Log M for Marker 
Proteins 
The R^ value obtained from Figs. 21-23 was plotted 
against Log M for marker proteins. The marker 
proteins were: 
A) Ribonuclease A 
B) X -Chymotrypsinogen A 
C) Ovalbumin 
D) BSA 
Thiol proteinase inhibitors are indicated by arrow: 
I) TPI-1 
III) TPI-3 
IV) TPI-4 
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Fig. 21 
SDS PAGE of Thiol Proteinase Inhibitor-1 and Marker 
Proteins 
25 jag each of TPI-1 and marker proteins was 
subjected to electrophoresis in 7.5% gel containing 
0.2% SDS for 4 hours at 50 V. Prior to electro-
phoresis the protein was denatured by heating at 
100°C for 5 minutes with sample buffer containing 
2-mercaptoethanol. 
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Fig. 22 
SDS PAGE of Thiol Proteinase Inhibitor-3 and Marker 
Proteins 
25 each of TPI-3 and marker proteins was 
subjected to electrophoresis in 7.5% gel containing 
0.2% SDS for 4 hours at 50 V. Prior to electro-
phoresis, the protein was denatured by heating at 
100°C for 5 minutes with sample buffer containing 
2-mercaptoethanol. 
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Fig. 23 
SDS PAGE of Thiol Proteinase Inhibitor-4 and Marker 
Proteins 
25 pg each of TPI-4 and marker proteins was 
subjected to electrophoresis in 7.5% gel containing 
0.2% SDS for 4 hours at 50 V. Prior to electro-
phoresis, the protein was denatured by heating at 
100°C for 5 minutes with sample buffer containing 
2r'mercaptoethanol. 
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Fig. 24 
Effect of pH on Thiol Proteinase Inhibitors 
65, 95 and 140 pg of TPI-1, TPI-3 and TPI-4 were 
incubated v/ith lOmM sodium acetate buffer pH 3.0 -
6.0, phosphate buffer pH 7.0 - 8.0 and Tris-HCl 
buffer pH 9.0 for 30 min. at 37°C. After 
incubation, the mixtures were neutralized with 
0.01 M phosphate buffer, pH 8.0 and then 22 pg of 
papain was added and the mixtures were incubated 
for 60 min. at 37°C. The following procedure was 
the same as described in "Methods" for inhibition 
assay using BAPNA as substrate. The activity of 
papain in the absence of inhibitors at pH 8.0 was 
taken as 100. 
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(E) Effect of Temperature 
The effect of exposure to temperature between 
30°-90°C is shown in Fig. 25. Very marked difference in 
temperature labilities between the inhibitors was 
observed. Inhibitor-4 was found most thermostable and 
retained complete inhibitory activity even after exposure 
to 70°C for 30 min. The thermostability of inhibitor-1 
and 3 were comparable and the preparation gradually lost 
inhibitory activity on exposure to temperature greater 
than 50°C. 
(F) Effect on K and V of Papain m max 
In order to understand the nature of inhibition of 
the isolated TPI' s their effect on K and V m max 
values of papain was determined by double reciprocal plot 
(142). For this purpose appropriate quantities of papain 
was incubated with 0.4 - 1.6 yjM BAPNA in presence or 
absence of the inhibitors 1, 3 and 4 (Fig. 26-28). All 
the three inhibitors appeared competitive in nature with 
significantly increased K without altering the V . The m max 
K^ value of papain for BAPNA was 1.67 x M. This was 
increased to 2.7 x lO"^ M (Fig. 26), 3.2 x lO"^ M (Fig. 27) 
and 3.6 x lO"^ M (Fig. 28) for the inhibitors 1, 3 and 4. 
(G) K^ determinations 
K^ values have been determined by working at lower 
Fig. 25 
Effect of Temperature on Thiol Proteinase 
Inhibitory Activity 
30 /ag, 20 J^ g and 45 /ig of TPI-1, TPI-3 and TPI-4 in 
0.01 M phosphate buffer, pH 8.0, were incubated at 
various temperatures for 30 min. and then rapidly 
cooled. 11 ;ag of papain was added and kept for 
60 min. at 37°C and then the remaining procedure 
was the same as described in "Methods" for 
inhibition assay using BAPNA as substrate. The 
inhibitory activity of inhibitors at 40°C was taken 
as 100. 
( ^  ) TPI-1 
( • ) TPI-3 
( O ) TPI-4 
50 60 70 
TEMPERATURE (®C ) 
Fig. 26 
Effect on K and V of Papain by Thiol Proteinase jn max 
Inhibitor-1 
90 /jg of thiol proteinase inhibitor-1 was incubated 
with 22 ;jg of papain at 37°C for 30 min. in 0.01 M 
phosphate buffer, pH 8.0 which was then incubated 
with varying concentration of BAPNA as substrate 
(0.4 - 1.6 juM) for 60 min. at 37°C. The following 
procedure was the same as described in "Methods" 
for inhibition assay. 
( » ) Papain 
(A ) Thiol Proteinase Inhibitor-1 

Fig. 27 
Effect on K and V of Papain by Thiol Proteinase m max 
Inhibitor-3 
Experimental details are the same as in Fig. 26. 

Fig. 28 
Effect on K and V of Papain by Thiol Proteinase m max 
Inhibitor-4 
Experimental details are the same as in Fig. 26. 
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papain concentrations, which favour the dissociation of 
the complexes, and using the steady state equation derived 
by Krupka and Laidler (143). This may be linearized as 
follows (Henderson, 109) 
1 + ° ^ = K. l-v./v 1 
1 o 
K m 
V . 
V O 
where [1] , [EJ and [S] ar-e the initial concentration of o o o 
inhibitor, enzyme and substrate respectively, v^ is the 
velocity without inhibitor and v^ is the velocity in the 
presence of inhibitor. The plot of [ I ] ( 1 - v ^ / v ^ ) against 
v^/v^ is a straight line (Figs. 29-31), the slope of which 
gives: 
^i(app.) = ^i ^^ m 
The K., . value obtained from the plot were 14.8xlO~^^M X \ Cl ^  ^ • / 
for TPI-1 (Fig. 29), 1.33xlO~^°M for TPI-3 (Fig. 30) and 
1.17xlO~^°M for TPI-4 (Fig. 31). 
(H) Specificity of the TPI's 
The inhibitory specificity of all the three TPI's 
with papain, trypsin and cathepsin-B (22 /ag) were made 
using BAPNA as substrate. None of the inhibitors showed 
any inhibition with the non-cysteine proteinase trypsin. 
Cathepsin-B and papain were inhibited by all the three 
inhibitors although papain was more strongly inhibited as 
Fig. 29 
Plot for K^ Determination of Thiol Proteinase 
Inhibitor-l 
30-160 ;jg of TPI-1 was incubated with 22 /ig of 
papain at 37°C for 30 min. The following procedure 
was the same as described in "Methods" for 
inhibition assay using BAPNA as substrate. 
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Fig. 30 
Plot for K^ Determination of Thiol Proteinase 
Inhibitor-3 
20-150 ;ag of TPI-3 was incubated with 22 jug of 
papain at 37°C for 30 min. The following procedure 
was the same as described in "Methods" for 
inhibition assay using BAPNA as substrate. 
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Fig. 31 
Plot for K^ Deterroination of Thiol Proteinase 
Inhibitor-4 
22-150 /ug of TPI-4 was incubated with 22 ;ug of 
papain at 37°C for 30 min. The following procedure 
was the same as described in "Methods" for 
inhibition assay using BAPNA as substrate. 
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compared to cathepsin-B by all the three inhibitors. 
Figs. 32-34 show the inhibition of different proteinases 
by TPI-1, TPI-3 and TPI-4 respectively. 
{I) Carbohydrate Content 
All the three TPI's were determined to be glyco-
protein, their neutral hexose content was determined using 
phenol sulphuric acid method of Dubois et al (135). With 
1 mg of TPI-1 in 1 ml solution corresponded to 40 /ag of 
neutral hexose, while it came out to be 367 . 5 /ig for TPI-3 
and for TPI-4 it was 195.6 /ig. The corresponding value of 
% carbohydrate content was 4% for TPI-1, 36.8% for TPI-3 
and 19.6% for TPI-4. The extent of glycosylation is 
given in Table 8'. 
(J) Stoichiometry 
Stoichiometries of binding of the thiol proteinase 
inhibitors were determined by titrations of the papain 
v/ith the three inhibitors using BAPNA as substrate. 
Experiments monitored by measurements of inhibition gave a 
papain/inhibitor for TPI-1 1:1 (Fig. 35). Similarly, a 
stoichiometry of 1.5:1 for TPI-3 (Fig. 36) and 3.2:1 for 
thiol proteinase inhibitor-4 was obtained (Fig. 37). 
(K) Optical Properties 
The ultraviolet absorption spectra of the three 
Fig. 32 
Specificity of Thiol Proteinase Inhibitor-1 
30, 65 and 130 pg of TPI-1 was incubated with 22 ;ag 
each of papain and trypsin in 0.01 M phosphate 
buffer, pH 8.0 while with 22 jug of cathepsin B, 
0.01 M sodium citrate buffer, pH 6.0 was used for 
30 min. at 37°C. The following procedure was the 
same as described in "Methods" for inhibition assay 
using BAPNA as substrate. 
( o ) with Trypsin 
( A ) With Cathepsin B 
( • ) with Papain. 
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Fig. 33 
Specificity of Thiol Proteinase Inhibitor-3 
22.5, 45, 67.5, 95 and 117.5 pg of TPI-3 was used. 
Rest of the experimental details are the same as in 
Fig. 32. 
( O ) with Trypsin 
(A ) with Cathepsin B 
( ® ) with Papain. 
TOO I-
A5 95 135 
INHIBITOR (jug ) 
Fig. 34 
Specificity of Thiol Proteinase Inhibitor-4 
22.5 , 45 , 67 . 5, 90, 112 .5 and 135 }iq of TPI-4 was 
used. Rest of the experimental details are the 
same as in Fig. 32. 
( O ) with Trypsin 
( A ) with Cathepsin B 
( • ) with Papain. 
100 r 
A 5 90 135 
INHIBITOR (>ig) 
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Table 8 
CARBOHYDRATE CONTENT OF THIOL PROTEINASE INHIBITORS 
Inhibitors Neutral Hexose Content Moles of neutral 
hexose/mole of 
ug/mg % protein 
TPI-1 40 4 15.5 
TPI-3 367.5 36.8 399 
TPI-4 195.6 19.6 539 
Fig. 35 
Stoichiometry Ratio Between Papain and Thiol 
Proteinase Inhibitor-1 
65 ;ug of TPI-1 was titrated with 8 - 30 /ig of 
papain using BAPNA as substrate. Inhibition assay 
was carried out as described in "Methods". 
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Fig. 36 
Stoichiometry Ratio Between Papain and Thiol 
Proteinase Inhibitor-3 
120 /ig of TPI-3 v/as titrated with 14-56 /ag of 
papain using BAPNA as substrate. Inhibition assay 
was carried out as described in "Methods". 
100 
80 
z 
o 
CD 60 
X 
UJ u 
cr 
UJ a 
AO 
20 
0 
1 2 3 A 5 
PAPAIN / INHIBITOR ( 
Fig. 37 
Stoichiometry Ratio Between Papain and Thiol 
Proteinase Inhibitor-4 
150 jaq of TPI-4 was titrated with 10 - 56 /ig of 
papain in using BAPNA as substrate. Inhibition 
assay was carried out as described in "Methods". 
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inhibitors were measured in lOmM phosphate buffer, pH 8.0 
in the wavelength region 250-340 nm. The papain and the 
thiol proteinase inhibitors 1, 3 and 4 absorbed maximally 
at 280 nm as shown in Figs. 38-40. The complex of papain 
and inhibitors also absorbed maximally at 280 nm with 
decrease in the absorbance of papain as shown in 
Figs. 38-40 with TPI-1, TPI-3 and TPI-4 respectively. 
The fluorescence emission spectra was also measured 
in the above buffer. The results are graphically shown in 
Figs. 41-43, where it can be seen that at an excitation 
wavelength of 280 nm maximum emission of all the three 
inhibitors occurred near 335 nm while that of papain alone 
had maximum emission at 350 nm. When the inhibitor was 
added to papain, fluorescence of the papain decreases 
considerably as shown in Figs. 41-43 with TPI-1, TPI-3 and 
TPI-4 respectively at 335 nm. 
Fig. 38 
Ultraviolet Absorption Spectra of TPI-1^ Papain and 
TPI-l-Papain Complex 
The spectra of TPI-1 (30 pg/3 ml in 0.01 M 
phosphate buffer, pH 8.0), papain (11 /ag/3 ml in 
0.01 M phosphate buffer, pH 8.0) and papain-TPI-1 
complex was recorded in the wavelength region of 
250 - 340 nm. 
( ® ) TPI-1 
( O ) Papain alone 
( A ) Papain—TPI-1 complex. 
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Fig. 39 
Ultraviolet Absorption Spectra of TPI-3 , Papain and 
TPI-3-Papain Complex 
The spectra of TPI-3 (30 /ag/3 ml in 0.01 M 
phosphate buffer, pH 8.0), papain (11 /ag/3 ml in 
0.01 M phosphate buffer, pH 8.0) and TPI-3—papain 
complex was recorded in the wave length region of 
250 - 340 nm. 
( » ) TPI-3 
( O ) Papain alone 
(A ) Papain—TPI-3 complex. 
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Fig. 40 
Ultraviolet Absorption Spectra of TPI-4 , Papain and 
TPI-4-Papain Complex 
The spectra of TPI-4 (30 /ag/3 ml in 0.01 M 
phosphate buffer, pH 8.0), papain (11 jag/3 ml in 
0.01 M phosphate buffer, pH 8.0) and TPI-4-papain 
complex was recorded in the wavelength region of 
250 - 340 nm. 
( ® ) TPI-4 
( O ) Papain alone 
(A ) Papain—TPI-4 complex. 
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Fig. 41 
Fluorescence Spectra of TPI-1 , Papain and TPI-1 
Papain Complex 
The spectra of TPI-1 (25 /ig/2,5 ml in 0.01 M 
phosphate buffer, pH 8.0), papain (2.7 /ig/2.5 ml in 
0.01 M phosphate buffer, pH 8.0) and TPI-1—papain 
complex was recorded in the wavelength region of 
250 - 400 nm. 
(A) Papain alone 
(B) TPI-1 
(C) TPI-1—papain complex. 
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Fig, 42 
Fluorescence Spectra of TPI-3, Papain and TPI-3 
Papain Complex 
The spectra of TPI-3 (25 ;ag/2.5ml in 0.01 M 
phosphate buffer, pH 8.0), papain (2.7 ;Lig/2.5 ml in 
0.01 M phosphate buffer, pH 8.0) and TPI-3-papain 
complex was recorded in the wavelength region of 
250 - 400 nm. 
(A) Papain alone 
(B) TPI-3 
(C) TPI-3-papain complex. 
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Fig. 43 
Fluorescence Spectra of TPI-4, Papain and TPI-4 
Papain Complex. 
The spectra of TPI-4 (25 pq/2.5 ml in 0.01 M 
phosphate buffer, pH 8.0), papain (2.7 /ag/2.5 ml in 
0.01 M phosphate buffer, pH 8.0) and TPI-4— papain 
complex was recorded in the wavelength region of 
250 - 400 nm. 
(A) Papain alone 
(B) TPI-4 
(C) TPI-4—papain complex. 
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Proteinase inhibitors specific for thiol proteinases 
play very important role in the prevention of unwanted 
proteolysis in blood. These inhibitors generally exist in 
human plasma in two major molecular forms differing in 
molecular weight i.e. HMW-TPI (MW 108,000 - 120,000) and 
LMW-TPI (MW 50,000 - 78,000). To the best of our 
knowledge there is only one study by Sasaki et al (42) in 
which they resolved three multimolecular forms of thiol 
proteinase inhibitor from human plasma. Clinically TPI is 
of great significance^ since all of the known human 
hereditary deficiencies of TPI involve essentially 
complete lack of HMW-TPI with levels of LMW-TPI ranging to 
different extents (84). It was envisaged that a thorough 
and systematic study of TPI's will be useful in under-
standing the physiological function of the TPI's for which 
development of a simple isolation procedure is a 
prerequisite. 
Purification of TPI from human plasma had been 
reported by a variety of laboratories (29, 41, 45-50). In 
general, purification of TPI's require many steps and the 
recovery from plasma was very lo\i?. The purification 
procedures reported by many investigators (51-54) include 
ion-exchange column chromatography, gel filtration, 
immunoaffinity chromatography and starch block electro-
phoresis. Most of the workers extensively used affinity 
chromatography using CNBr-activated chromagel A-2 (29), 
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papain - sepharose 4B (28), trypsin-chymotrypsin-chromagel 
A-2 (42), CNBr-activated sepharose CL 4B (50) and CM 
papain-sepharose (43). As most of these methods involve 
affinity chromatography, several chromatographic runs 
would be needed for the preparation of proteinase 
inhibitor in relatively large quantities. The isolation 
procedure used in the present study is a modification of 
the method described by Sasaki et al (42). By employing 
ammonium sulphate fractionation (35-55%), gel 
chromatography on Sephadex G-200 (Fig. 2) and ion-exchange 
chromatography using DEAE-cellulose column (Figs. 5-8), 
four molecular forms of TPI from human plasma had been 
isolated. Out of the four, three inhibitors were purified 
to near homogeneity (Figs. 9, II, 12). The procedure 
developed in this study is superior to that of the 
previous workers firstly in having less and simple three 
purification steps which are particularly suitable for the 
rapid preparation of plasma thiol proteinase inhibitor in 
a relatively larger amounts. Secondly, four 
multimolecular forms of TPI had been isolated as compared 
to three reported by Sasaki et al (42). Thirdly, high 
yield of 10-18% and fold purification of 281-1099 for the 
four inhibitors were obtained as compared to low yield of 
8-12% and 268 fold purification reported in literature 
(28, 50) (Table 5). However, the difference in the 
inhibitory activity units between ammonium sulphate 
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fractionation (208 units) and the sum of the four peaks of 
Sephadex G-200 (489 units) is anamolous. This may be due 
to the presence of some crude proteins which interfere 
with the inhibitory activity at the ammonium sulphate 
step. 
As mentioned earlier, human plasma comprises of 
LMVJ-TPI (61) and HMW-TPI (84 , 144 , 145). In the present 
study, we obtained a molecular form of 70,000 (TPI-1) 
closer to LMW-TPI (68,000) reported by Muller-Esterl et al 
(50) and Gounaris et al (43) and a heterogeneous peak of 
TPI with molecular weight of 155,000 (TPI-2) close to 
120,000 reported by Nakayasu et al (128). On the basis of 
molecular weight we assumed that the TPI-2 was HMW-TPI. We 
have not characterized this inhibitor in detail because we 
were more interested in the two additional multimolecular 
forms of the inhibitors. Secondly, it was obtained in 
heterogeneous form by our simple purification procedure. 
The two additional inhibitors had been isolated to a 
functionally pure state with a molecular weights of 
195,000 and 497,000 respectively. Thiol proteinase 
inhibitor-I (MW 70,000), TPI-3 (MW 195,000) and TPI-4 
(MW 49 7,000) showed near charge homogeneity in 5% PAGE 
while TPI-2 (MW 155,000) showed charge heterogeneity 
(Figs. 9-12), but all the four inhibitors were homogeneous 
on the basis of size on Sephadex G-200 (Fig. 15). We have 
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centered our experiments on and inhibitory 
peaks which were obtained in a functionally pure state. 
Our result suggest that molecular forms obtained were not 
due to an artifacts of the isolation procedure, since 
elution profile on Sephadex G-200 column were found to be 
highly reproducible in eight separate experiments with 
outdated human plasma. In addition, purification was also 
carried out with plasma isolated from fresh human blood on 
Sephadex G-150 column, which also gave the same elution 
profile (Fig. 3). When human plasma was subjected to gel 
chromatography on Sephadex G-150 column, it again gave 
same elution profile with four thiol proteinase inhibitory 
peaks (Fig. 4). It is difficult to speculate the reasons 
for the discrepancy in the number of the TPI's reported by 
various workers. Ryley (41) reported two forms, while 
Sasaki et al (42) reported three forms of TPI in human 
plasma. Although all possible precautions have been taken 
in the present study and presumably those of others. The 
possibility of proteolysis taking place during 
purification can not be completely ruled out since a large 
number of proteinases are known to be released during the 
isolation and storage of blood. One possible explanation 
that needs further support is that all the inhibitors are 
derived from the single subunit TPI-1. In viewing the 
lower subunit molecular weight of TPI-3 and even lower 
subunit molecular weight of TPI-4, it can be hypothesized 
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that cleavage of TPI-1 in certain fashion may result in 
its association in the form of a tetramer (TPI-3). 
Similarly, a proteolytic cleavage leading to even smaller 
form can lead to its aggregation resulting in oligomer 
with ten subunits (TPI-4). While cross-reactivity of the 
three forms (Figs. 13-14) support this hypothesis, further 
experiment are needed to substantiate this. 
Hydrodynamic parameters of TPI's as determined from 
its gel filtration behaviour from a calibrated Sephadex 
G-200 column suggested a stokes radius of 3.43 nm, 4.45 nm^ 
4.82 nm and 6.47 nm for TPI-1, TPI-2, TPI-3 and TPI-4 
respectively (see Figs. 18-19 and Tables 6 and 7). 
Frictional ratios f/f^ were computed from their stokes 
radius and were found to be 1.3, 1.25, 1.26 and 0.92 for 
TPI-1, TPI-2, TPI-3 and TPI-4 respectively. These results 
suggested that all the four TPI's possess a globular 
conformation under native conditions. The significant 
deviation from globular shape (1) may be attributed to 
substantial glycosylation of the inhibitors. 
Summary of the important properties of the thiol 
proteinase inhibitors investigated in this study are 
listed in Table 9. 
Molecular weight under native condition by gel 
chromatography on Sephadex G-200 column was 70 KD for 
TPI-1, 155 KD for TPI-2, 195 KD for TPI-3 and 497 KD for 
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Table 9 
SOME PROPERTIES OF THIOL PROTEINASE INHIBITORS 
S.No. Properties Value^ 
TPI-1 TPI-3 TPI-4 
1. Molecular mass by 
SDS-PAGE (KD) 
69 56 52 
2. Molecular mass by 
gel filtration on 
Sephadex G-200 (KD) 
70 195 497 
3. Stokes radius (nm) 3.43 4.82 6.47 
4. Frictional ratio 1.3 1.26 0.92 
5. Neutral hexose 
content (%) 
4 36.8 19.6 
6. pH stability above 5.0 5.0 5.0 
7 . Heat stability upto 40°C 40°C 70°C 
8. Km value (M) 2.7x10"® 3.2x10"® 3.6x10" 
9. Kj. value (M) 14.8x10"^° 1.33x10" 1.17x10 
10. Proteinases 
inhibited 
papain, 
cathepsin 
-do-
B 
-do-
11. Proteinases not 
inhibited 
Trypsin -do- -do-
12. Stoichiometry 
ratio (E/I) 
1:1 1.5:1 3.2:1 
13. Cross reactivity 
against anti-I TPI 
+ + + 
14. Absorption maximum 
(nm) 
280 280 280 
15. Fluorescence 
emission maximum (nm) 
335 335 335 
This study 
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TPI-4 (Figs. 15-17), whereas the molecular weight of the 
TPI's by SDS-PAGE under denaturing conditions in the 
presence of ^-mercaptoethanol was found to be 69 KD for 
TPI-1 which is about 1.4% lower than that of 70 KD 
determined by gel filtration, whereas TPI-3 and TPI-4 gave 
a molecular weight of 56 KD and 52 KD respectively under 
similar conditions (Figs. 20-23). When SDS-PAGE was done 
in the absence of B-mercaptoethanol, single protein bands 
were obtained at positions corresponding to molecular 
weight of 69 KD, 224 KD and 520 KD for TPI-1, TPI-3 and 
TPI-4 respectively. These result suggested that the 
inhibitor-1 is a single polypeptide chain, but inhibitor-3 
and inhibitor-4 contain four and ten subunits respectively 
of identical size which are held together by disulphide 
bonds. 
Sasaki et al (42), Ryley (41), Jarvinen (28) and 
Pagano et al (44) reported LMW-TPI in human plasma of 
MW 90,000. While Gounaris et al (43) and Muller-Esterl et 
al (50) purified LMW-TPI from human plasma of MW 64,000 
and 68,000 respectively. Muller-Esterl et al (50), Pagano 
et al (44) and Gounaris et al (43) reported LMW-TPI 
purified by them to be a single polypeptide chain. The 
TPI-1 (MW 70,000) isolated in this study is comparable to 
that isolated by Gounaris et al (43) and Muller-Esterl et 
al (50), on the basis of molecular weight determined by 
SDS-PAGE in the presence of p.-mercaptoethanol (Fig. 21) 
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which gave a value of 69,000 with a single polypeptide 
chain. 
All the thiol proteinase inhibitors isolated from 
human plasma in this study were found to be a glycoprotein. 
The neutral hexose content of TPI-1, TPI-3 and TPI-4 were 
4, 36.8 and 19.6% (W/W) respectively which corresponded to 
15.5, 399 and 539 moles of neutral hexose per mole of 
protein for the three inhibitors respectively (see 
Table 8). Thiol proteinase inhibitor-3 and 4 isolated in 
this study have substantially high carbohydrate content 
than TPI-1. Thiol proteinase inhibitors isolated from 
human plasma by Ryley (41), Nakayasu et al (128), 
Jarvinen (28), Muller-Esterl et al (50), Gounaris et al 
(43), Nagasawa et al (146) and Sakamoto et al (147) have 
also been shown to be glycoproteins with carbohydrate 
content ranging betv/een 3.6 - 10% respectively. This 
result is comparable with the 4% carbohydrate content 
obtained for TPI-1 in this study with those of Nakayasu et 
al (128). 
Experiments on the effect of pH on the activity of 
inhibitor ranging from pH 3.0 to pH 9.0 showed that all 
proteinase inhibitors were stable to exposure to pH 5.0 to 
9.0. The data of this experiment indicated pH dependent 
activation of the three inhibitors between pH 4.0 - pH 5.0 
However, below pH 5.0 all the three inhibitors were very 
107 
labile as is shown in Fig. 24 by their low inhibitory 
values. These results are in agreement with those of the 
multimolecular forms of TPI by Sasaki et al (42) and 
Taniguchi et al (148). 
When thermal activity studies were performed, the 
inhibitors-1 and 3 exhibited stability with decrease in 
inhibitory activity above 40 °C while inhibitor-4 showed 
optimum activity upto 70°C (Fig. 25). At 90°C only 0-5% 
inhibitory activity remained. Activity had been reported 
to be stable to temperatures in the range of 50°-90°C by 
Sasaki et al (42) and Taniguchi et al (148). Barrett et 
al (57) found the inhibitory activity of LMW-TPI to be 
stable to lOOoc for 5 minutes at neutral pH. 
The Kj^  values for papain in the presence of TPI-1, 
TPI-3 and TPI-4 from Lineweaver Burk plot (Figs. 26-28) 
came out to be 2.7 x 10~^ M, 3.2 x 10~® M and 3.6 x lO"® M 
respectively. However, the K^ value of papain in the 
absence of these inhibitors was found to be 1.67 x 10 ^ M. 
Moreover, j^jj^ j^  computed from the intercepts of the 
Lineweaver Burk plots for papain in the presence of TPI-1, 
TPI-3 and TPl-4 were 15.87 x 10~^ 15.15 x 10~^ and 
14.28 x 10~® pmole/ml/60 min. From the above result it 
can be concluded that the K^ value of papain increases in 
the presence of inhibitors with no change in V . Thus, 
this showed that the interaction of the inhibitors with 
papain was competitive in nature. 
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A ratio of ^cat^^m presence of 
inhibitor were calculated for papain to determine the 
efficiency of the inhibitors. The values with TPI-1, 
TPI-3 and TPI-4 turned out to be 8.'^  x M~^/sec, 
7.5 X 10^° M~^/sec and 7.2 x 10^° M~^/sec respectively. 
The data indicated that TPI-1 was more efficient in 
inhibiting the enzyme. 
A good inhibitor generally combines with the target 
enzyme with an apparent dissociation constant in the range 
of lO"^*^ M (149). All the three proteins were potent 
inhibitors of thiol proteinases can be well seen by their 
K^ values which was determined by Henderson's (109) method 
since it was readily apparent that the degree of 
inhibition varied with absolute concentration of the 
inhibitors as would be expected for tight binding 
reversible inhibition. The K., v values for TPI-1, i(app.) 
TPI-3 and TPI-4 obtained were 14.8 x M, 1.33 x 
M and 1.17 x M (Figs. 29-31) respectively. 
Hence from the value it was clearly seen that 
inhibitor-1 binds more tightly with the enzyme than 
inhibitor-3 which in turn was more potent when compared 
with TPI-4. A value of 0.34 x M for t?C-thiol 
proteinase inhibitor and 0.15 x M for LMW-TPI had 
been reported by Gounaris et al (43) and Barrett et 
al (150). 
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Specificity of the three proteins isolated in this 
study as proteinase inhibitors was carried out using 
papain, cathepsin-B and trypsin as enzymes. Similar 
result was obtained for the three inhibitors (Figs. 32-34) 
All TPI's inhibited the activities of papain on both low 
and high molecular weight substrates. All of them 
inhibited papain more strongly than cathepsin-B while 
trypsin was not inhibited at all. This result strongly 
suggests that all the three proteins are specific for 
thiol proteinases, and presumably require active thiol 
group for the binding. The observed difference in 
susceptibility among thiol proteinases suggest that the 
inhibition was not due to a simple stoichiometric 
combination. The poor inhibition of cathepsin B suggested 
that the enzyme affected by them was not cathepsin B, but 
may be one of the other thiol proteinases of tissues e.g. 
cathepsin C(151), H(6, 32, 152), L(7, 42, 152) or 
collagenolytic cathepsin (153). Thiol proteinase 
inhibitors (MW 90,000 and 175,000) purified from human 
serum by Jarvinen (28) strongly inhibited papain as 
compared to cathepsin B and did not inhibit trypsin at 
all. Thiol proteinase inhibitor isolated by Gounaris et 
al (43) also showed tight binding with papain (K^ 0.034nM) 
as compared to cathepsin L(K^ 0.062nM), H(K^ 0.062nM) and 
B(K^ 35/iM). Similar results were also obtained by Barrett 
et al (150), Salvesen et al (62) and Machleidt et al (126) 
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for human plasma thiol proteinase inhibitor (see Table 4). 
The inhibitors major role may be to regulate the neutral 
thiol proteinases that play important role in the 
inflammatory response (154). 
Stoichiometries of binding of the inhibitors with 
papain as determined by titration of papain with the 
TPI-1, TPI-3 and TPI-4 at high protein concentration. 
Experiments for the measurement of inhibition of papain by 
the inhibitors gave papain: inhibitor-1 stoichiometry of 
1:1, for inhibitor-3 it was 1.5:1 while for inhibitor-4 it 
turned out to be 3.2:1 (see Figs. 35-37). Salvesen et al 
(62) reported 2:1 (enzyme: inhibitor) stoichiometry, 
nevertheless Gounaris et al (43) pointed it to be 1:1 
stoichiometry for LMW-thiol proteinase inhibitor. The 
reason for this discrepancy was not clear. The structural 
relations of TPI-1, TPI-3 and TPI-4 and also for TPI-2 
were examined with antibody against inhibitor-1 by 
immunodiffusion test. The precipitin lines of all the 
four inhibitors against antibody of TPI-1 fused without 
spur formation. This result shows that all the inhibitors 
have similar antigenic structures, although their 
molecular weights are considerably different. Inhibition 
ELISA with anti-inhibitor-1 inhibited the inhibitory 
activities of TPI-1, TPI-3 and TPI-4 considerably. Thiol 
proteinase inhibitor-1 was inhibited to a greater extent 
than TPI-3 and TPI-4. This also indicated that the 
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inhibitors had similar antigenic structures (Figs. 13-14). 
The two TPI's isolated by Jarvinen (28) (MW 90,000 and 
175,000) on immunodiffusion gave single precipitin line 
with the antiserum raised against either of the two forms 
of the inhibitor showing that both were immunologically 
closely related. The multimolecular forms isolated by 
Sasaki et al (42) (P~l 90,000; P-2 95,000 and P-3 167,000) 
gave single precipitin arc against anti-P-3 antibody and 
fused without spur formation. Nakayasu et al (128), 
Muller-Esterl et al (50) and Gounaris et al (43) also 
found immunological identity between LMW-TPI and HMVJ-TPI. 
Optical properties of all the three inhibitors were 
similar (see Figs. 38-43). All of them absorb maximally 
near 280 nm in the wavelength region of 250-340 nm. 
Nakayasu et al (128) has also reported maximum absorption 
in the U.V. range at 280 nm. The absorbance of the papain 
decreases when inhibitors were added. Decre<^S€. o X IQorwy 
suggested that chromophoric groups were involved in the 
binding process. Fluorescence experiment showed maxima in 
excitation and emission spectra of the three TPI's at 280 
and 335 nm respectively. Maximum in the fluorescence 
emission spectrum of the inhibitor near 335 nm was 
indicative of the presence of tryptophan residue. Complex 
formation between papain and the inhibitors accompanies 
with a marked decrease in the fluorescence of papain at 
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335 nm. This result again indicated the involvement of 
chromophoric groups particularly tryptophan in the binding 
process. 
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